<SEC-DOCUMENT>0001493152-25-026697.txt : 20251208
<SEC-HEADER>0001493152-25-026697.hdr.sgml : 20251208
<ACCEPTANCE-DATETIME>20251208173014
ACCESSION NUMBER:		0001493152-25-026697
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		16
CONFORMED PERIOD OF REPORT:	20251207
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20251208
DATE AS OF CHANGE:		20251208

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Immix Biopharma, Inc.
		CENTRAL INDEX KEY:			0001873835
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				454869378
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-41159
		FILM NUMBER:		251557066

	BUSINESS ADDRESS:	
		STREET 1:		11400 WEST OLYMPIC BLVD.
		STREET 2:		SUITE 200
		CITY:			LOS ANGELES
		STATE:			CA
		ZIP:			90064
		BUSINESS PHONE:		(888) 958-1084

	MAIL ADDRESS:	
		STREET 1:		10573 W. PICO BLVD.
		STREET 2:		#58
		CITY:			LOS ANGELES
		STATE:			CA
		ZIP:			90064
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form8-k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:us-roles="http://fasb.org/us-roles/2025" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:IMMX="http://immixbio.com/20251207">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02E_US%2DGAAP%2D2025 -->
<!-- Field: Set; Name: xdx; ID: xdx_035_IMMX_immixbio.com_20251207 -->
<!-- Field: Set; Name: xdx; ID: xdx_048_20251207_20251207 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_05A_edei%2D%2DEntityCentralIndexKey_0001873835 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="AsOf2025-12-07" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2025-12-07" id="Fact000004" name="dei:EntityCentralIndexKey">0001873835</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="immx-20251207.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="AsOf2025-12-07">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001873835</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-12-07</xbrli:startDate>
        <xbrli:endDate>2025-12-07</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 4pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>UNITED
STATES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><b>WASHINGTON,
DC 20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>FORM
<span id="xdx_90F_edei--DocumentType_c20251207__20251207_zAVUHsjkTiXc"><ix:nonNumeric contextRef="AsOf2025-12-07" id="Fact000009" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CURRENT
REPORT</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Pursuant
to Section 13 or 15(d) of</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>the
Securities Exchange Act of 1934</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Date
of report (Date of earliest event reported): <span id="xdx_90A_edei--DocumentPeriodEndDate_c20251207__20251207_zsYqkMf7KvD4"><ix:nonNumeric contextRef="AsOf2025-12-07" format="ixt:datemonthdayyearen" id="Fact000010" name="dei:DocumentPeriodEndDate">December 7, 2025</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b><span id="xdx_904_edei--EntityRegistrantName_c20251207__20251207_zeL0WCqxC9c2"><ix:nonNumeric contextRef="AsOf2025-12-07" id="Fact000011" name="dei:EntityRegistrantName">IMMIX
BIOPHARMA, INC.</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact
Name of Registrant as Specified in Its Charter)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_903_edei--EntityIncorporationStateCountryCode_c20251207__20251207_zK1USeEVCbTc"><ix:nonNumeric contextRef="AsOf2025-12-07" format="ixt-sec:stateprovnameen" id="Fact000012" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><span id="xdx_90E_edei--EntityFileNumber_c20251207__20251207_zFyqGj4RQKDf"><ix:nonNumeric contextRef="AsOf2025-12-07" id="Fact000013" name="dei:EntityFileNumber">001-41159</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><span id="xdx_90E_edei--EntityTaxIdentificationNumber_c20251207__20251207_zhOsWSAnYF7i"><ix:nonNumeric contextRef="AsOf2025-12-07" id="Fact000014" name="dei:EntityTaxIdentificationNumber">45-4869378</ix:nonNumeric></span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State
                                            or Other Jurisdiction</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of
    Incorporation)</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Commission</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">File
    Number)</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(I.R.S.
                                            Employer</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identification
    Number)</span></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><span id="xdx_901_edei--EntityAddressAddressLine1_c20251207__20251207_zVKKo5rpIrJf"><ix:nonNumeric contextRef="AsOf2025-12-07" id="Fact000015" name="dei:EntityAddressAddressLine1">11400
West Olympic Blvd.</ix:nonNumeric></span>, <span id="xdx_903_edei--EntityAddressAddressLine2_c20251207__20251207_zrvaQDn49k4g"><ix:nonNumeric contextRef="AsOf2025-12-07" id="Fact000016" name="dei:EntityAddressAddressLine2">Suite 200</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><span id="xdx_902_edei--EntityAddressCityOrTown_c20251207__20251207_zGaJTQ90rzB9"><ix:nonNumeric contextRef="AsOf2025-12-07" id="Fact000017" name="dei:EntityAddressCityOrTown">Los
Angeles</ix:nonNumeric></span>, <span id="xdx_90B_edei--EntityAddressStateOrProvince_c20251207__20251207_z8g0bQrNNpI"><ix:nonNumeric contextRef="AsOf2025-12-07" id="Fact000018" name="dei:EntityAddressStateOrProvince">CA</ix:nonNumeric></span> <span id="xdx_90F_edei--EntityAddressPostalZipCode_c20251207__20251207_zZUrZNwSoPHc"><ix:nonNumeric contextRef="AsOf2025-12-07" id="Fact000019" name="dei:EntityAddressPostalZipCode">90064</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address
of principal executive offices)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><span id="xdx_90B_edei--CityAreaCode_c20251207__20251207_zoy4dCfhrxbg"><ix:nonNumeric contextRef="AsOf2025-12-07" id="Fact000020" name="dei:CityAreaCode">(310)</ix:nonNumeric></span>
<span id="xdx_90D_edei--LocalPhoneNumber_c20251207__20251207_zYdAaUbXlVAi"><ix:nonNumeric contextRef="AsOf2025-12-07" id="Fact000021" name="dei:LocalPhoneNumber">651-8041</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Registrant&#8217;s
telephone number, including area code)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under
any of the following provisions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_edei--WrittenCommunications_c20251207__20251207_zS2nMjqOH7v"><ix:nonNumeric contextRef="AsOf2025-12-07" format="ixt:booleanfalse" id="Fact000022" name="dei:WrittenCommunications">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Written
    communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_edei--SolicitingMaterial_c20251207__20251207_zXMWR32uSQo2"><ix:nonNumeric contextRef="AsOf2025-12-07" format="ixt:booleanfalse" id="Fact000023" name="dei:SolicitingMaterial">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting
    material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14d-2(b)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_edei--PreCommencementTenderOffer_c20251207__20251207_zD8Xp0tfV8ak"><ix:nonNumeric contextRef="AsOf2025-12-07" format="ixt:booleanfalse" id="Fact000024" name="dei:PreCommencementTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
    communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_edei--PreCommencementIssuerTenderOffer_c20251207__20251207_zimeBsKutpSc"><ix:nonNumeric contextRef="AsOf2025-12-07" format="ixt:booleanfalse" id="Fact000025" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
    communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Securities
registered pursuant to Section 12(b)of the Act:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 40%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title
    of each class</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Trading
    Symbol(s)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 40%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name
    of each exchange on which registered</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_edei--Security12bTitle_c20251207__20251207_zgyHnCh2bqo5"><ix:nonNumeric contextRef="AsOf2025-12-07" id="Fact000026" name="dei:Security12bTitle">Common
    Stock, par value of $0.0001 per share</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_edei--TradingSymbol_c20251207__20251207_z6Q6Tm3Xtxoc"><ix:nonNumeric contextRef="AsOf2025-12-07" id="Fact000027" name="dei:TradingSymbol">IMMX</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_edei--SecurityExchangeName_c20251207__20251207_zr8sqHYgnq3j"><ix:nonNumeric contextRef="AsOf2025-12-07" format="ixt-sec:exchnameen" id="Fact000028" name="dei:SecurityExchangeName">The
    Nasdaq Stock Market LLC</ix:nonNumeric></span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 4in; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 4in; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
growth company <span id="xdx_908_edei--EntityEmergingGrowthCompany_c20251207__20251207_zIhnKhZZ74Pj"><ix:nonNumeric contextRef="AsOf2025-12-07" format="ixt:booleantrue" id="Fact000029" name="dei:EntityEmergingGrowthCompany">&#9746;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 4in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <span id="xdx_901_edei--EntityExTransitionPeriod_c20251207__20251207_zL8UGRF17PK9"><ix:nonNumeric contextRef="AsOf2025-12-07" format="ixt:booleanfalse" id="Fact000030" name="dei:EntityExTransitionPeriod">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 4pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
1.01. Entry into a Material Definitive Agreement.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Underwritten
Registered Offering</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 7, 2025, Immix Biopharma, Inc., a Delaware corporation (the &#8220;<span style="text-decoration: underline">Company</span>&#8221;), entered into an underwriting agreement
(the &#8220;<span style="text-decoration: underline">Underwriting Agreement</span>&#8221;) with Morgan Stanley &amp; Co. LLC, as representative of the several underwriters named
in Schedule 1 thereto (the &#8220;<span style="text-decoration: underline">Underwriters</span>&#8221;), relating to the issuance and sale (the &#8220;<span style="text-decoration: underline">Offering</span>&#8221;)
of 19,117,646 shares of its common stock, par value $0.0001 per share (the &#8220;<span style="text-decoration: underline">Shares</span>&#8221;), and pre-funded warrants to purchase
490,196 shares of its common stock (the &#8220;<span style="text-decoration: underline">Pre-Funded Warrants</span>&#8221;). The Shares are being sold at a price of $5.10 per
share and the Pre-Funded Warrants are being sold at a price of $5.09 per Pre-Funded Warrant, which represents the per share offering
price for the Shares minus the $0.01 per share exercise price for each Pre-Funded Warrant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
Pre-Funded Warrant will have an exercise price per share of common stock equal to $0.01 per share. The exercise price and the number
of shares of common stock issuable upon exercise of each Pre-Funded Warrant is subject to appropriate adjustments in the event of certain
stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting the common stock.
Each Pre-Funded Warrant will be exercisable on or after the date of issuance until the date the Pre-Funded Warrant is exercised in full.
Each Pre-Funded Warrant will be exercisable, in the holder&#8217;s discretion, by (i) payment in full in immediately available funds
for the number of shares of common stock purchased upon such exercise or (ii) a cashless exercise, in which case the holder would receive
upon such exercise the net number of shares of common stock determined according to the formula set forth in the Pre-Funded Warrant.
Under the Pre-Funded Warrants, the Company may not effect the exercise of any Pre-Funded Warrant, and a holder will not be entitled to
exercise any portion of any Pre-Funded Warrant that, upon giving effect to such exercise, would cause: (i) the aggregate number of shares
of common stock beneficially owned by such holder (together with its affiliates) to exceed 4.99% of the total number of shares of common
stock outstanding immediately after giving effect to the exercise; or (ii) the combined voting power of the Company&#8217;s securities
beneficially owned by such holder (together with its affiliates) to exceed 4.99% of the combined voting power of all of the Company&#8217;s
securities immediately outstanding after giving effect to the exercise, as such percentage ownership is determined in accordance with
the terms of the Pre-Funded Warrant, which percentage may be changed at the holder&#8217;s election to a higher or lower percentage not
in excess of 19.99% upon at least 61 days&#8217; notice to the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 27pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event of certain fundamental transactions, a holder of Pre-Funded Warrants will be entitled to receive, upon exercise of the Pre-Funded
Warrants, the kind and amount of securities, cash or other property that such holder would have received had they exercised the Pre-Funded
Warrants immediately prior to the fundamental transaction without regard to any limitations on exercise contained in the Pre-Funded Warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 27pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Offering is being made pursuant to a shelf registration statement filed January 3, 2023 and declared effective by the Securities and
Exchange Commission (the &#8220;<span style="text-decoration: underline">SEC</span>&#8221;) on January 11, 2023 (the &#8220;<span style="text-decoration: underline">Registration Statement</span>&#8221;) (File. No. 333-269100),
a base prospectus filed as part thereof, and a prospectus supplement dated December 7, 2025, filed pursuant to Rule 424(b)(5) under the
Securities Act of 1933, as amended (the &#8220;<span style="text-decoration: underline">Securities Act</span>&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Underwriting Agreement contains customary representations, warranties and agreements by the Company, customary conditions to closing,
and customary indemnification obligations of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
foregoing summary of the terms of the Underwriting Agreement and the Pre-Funded Warrants is subject to, and qualified in its entirety
by reference to, the full texts of the Underwriting Agreement and form of Pre-Funded Warrant that are filed as <span style="text-decoration: underline">Exhibits 1.1</span> and
<span style="text-decoration: underline">4.1</span> to this Current Report on Form 8-K and are incorporated herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 27pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
opinion of The Loev Law Firm, PC, regarding the validity of the Shares and Pre-Funded Warrants, and the shares of common stock underlying
the Pre-Funded Warrants in connection with this Offering, is filed herewith as <span style="text-decoration: underline">Exhibit 5.1</span> and is incorporated by reference into
the Registration Statement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
net proceeds to the Company from the Offering, after deducting underwriting discounts and commissions, and estimated offering expenses,
are expected to be approximately $93.7 million. The Offering is expected to close on December 9, 2025, subject to the satisfaction of
customary conditions. The Company may receive nominal proceeds, if any, from the exercise of the Pre-Funded Warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 27pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
9.01 Financial Statements and Exhibits.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
Exhibits.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 0.75in"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>No.</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex1-1.htm">Underwriting Agreement, dated December 7, 2025, by and between Immix Biopharma, Inc. and Morgan Stanley &amp; Co. LLC, as representative of the several underwriters</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex4-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Pre-Funded Warrant</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex5-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal Opinion of The Loev Law Firm, PC</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex5-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent of The Loev Law Firm, PC (contained in Exhibit 5.1).</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover
    Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNATURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Immix
    Biopharma, Inc.</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated:
    December 8, 2025</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Ilya Rachman</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ilya
    Rachman, Ph.D., M.D.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 3; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjVsKwkAMRVfQPYT5ltoHivRPi4pYRYqIv4ONMthOSmZ8LcldGlvEEMjrnhulBmpJC1Mjw3FWFrDHpq21RyjxjIz2hKLIV+sMpJZ4Mc6ztr4bf2BOwqAw4zDVsu+Ud+OwyiBOhtFkmIykyUYpTDcq+N5zsmdTofVG16BtBTumlg16za/eYa+fZKl5dZ8OyM6QFbsw6s9vSKI4gS3d9YP46qAochUMugjUkunWimr+9Gi/JMxrbOSd6+l/Bh/Es0pQ -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>ex1-1.htm
<DESCRIPTION>EX-1.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
1.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IMMIX
BIOPHARMA, INC.</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19,117,646
SHARES OF COMMON STOCK, PAR VALUE $0.0001 PER SHARE</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PRE-FUNDED
WARRANTS TO PURCHASE 490,196 SHARES OF COMMON STOCK</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">UNDERWRITING
AGREEMENT</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
7, 2025</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
7, 2025</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Morgan
Stanley &amp; Co. LLC</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c/o Morgan Stanley &amp; Co. LLC</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.25in; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1585
Broadway</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.25in; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
York, New York 10036</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ladies
and Gentlemen:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Immix
Biopharma Inc., a Delaware corporation (the &ldquo;<B>Company</B>&rdquo;), proposes to issue and sell to the several underwriters named
in <U>Schedule I</U> hereto (the &ldquo;<B>Underwriters</B>&rdquo;), for whom Morgan Stanley &amp; Co. LLC is acting as representative
(the &ldquo;<B>Representative</B>&rdquo;), (i) 19,117,646 shares of its common stock, par value $0.0001 per share (the &ldquo;<B>Shares</B>&rdquo;)
and (ii) pre-funded warrants to purchase up to 490,196 shares of the Company&rsquo;s common stock (the &ldquo;<B>Pre-Funded Warrants</B>&rdquo;
and, together with the Shares, the &ldquo;<B>Securities</B>&rdquo;) at an exercise price of $0.01 per share. The shares of the Company&rsquo;s
common stock issuable upon exercise of the Pre-Funded Warrants are herein referred to as the &ldquo;<B>Warrant Shares</B>.&rdquo; The
shares of common stock, par value $0.0001 per share, of the Company to be outstanding after giving effect to the sales contemplated hereby
are hereinafter referred to as the &ldquo;<B>Common Stock.</B>&rdquo;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has filed with the Securities and Exchange Commission (the &ldquo;<B>Commission</B>&rdquo;) a shelf registration statement on
Form S-3 (File No. 333-269100), including a prospectus relating to certain securities, including common stock, preferred stock, debt
securities, warrants and units, to be issued from time to time by the Company (the &ldquo;<B>Base Prospectus</B>&rdquo;). The registration
statement as amended at the time it became effective, including the information (if any) deemed to be part of the registration statement
at the time of effectiveness pursuant to Rule 430A under the Securities Act of 1933, as amended (the &ldquo;<B>Securities Act</B>&rdquo;),
is hereinafter referred to as the &ldquo;<B>Registration Statement</B>&rdquo;; the Base Prospectus and the final prospectus supplement
in the form first used to confirm sales of Securities (or in the form first made available to the Underwriters by the Company to meet
requests of purchasers pursuant to Rule 173 under the Securities Act) is hereinafter referred to as the &ldquo;<B>Prospectus.</B>&rdquo;
If the Company has filed an abbreviated registration statement to register additional shares of Common Stock pursuant to Rule 462(b)
under the Securities Act (a &ldquo;<B>Rule 462 Registration Statement</B>&rdquo;), then any reference herein to the term &ldquo;<B>Registration
Statement</B>&rdquo; shall be deemed to include such Rule 462 Registration Statement.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
purposes of this Agreement, &ldquo;<B>free writing prospectus</B>&rdquo; has the meaning set forth in Rule 405 under the Securities Act,
&ldquo;preliminary prospectus&rdquo; shall mean the Base Prospectus that omitted information pursuant to Rule 430A under the Securities
Act that was used after such effectiveness and prior to the execution and delivery of this Agreement, &ldquo;<B>Time of Sale Prospectus</B>&rdquo;
means the preliminary prospectus together with the documents and pricing information set forth in <U>Schedule II</U> hereto, and &ldquo;<B>broadly
available road show</B>&rdquo; means a &ldquo;bona fide electronic road show&rdquo; as defined in Rule 433(h)(5) under the Securities
Act that has been made available without restriction to any person. As used herein, the terms &ldquo;Registration Statement,&rdquo; &ldquo;preliminary
prospectus,&rdquo; &ldquo;Time of Sale Prospectus&rdquo; and &ldquo;Prospectus&rdquo; shall include the documents, if any, incorporated
by reference therein as of the date hereof. The terms &ldquo;<B>supplement,</B>&rdquo; &ldquo;<B>amendment</B>&rdquo; and &ldquo;<B>amend</B>&rdquo;
as used herein with respect to the Registration Statement, the Prospectus, the Time of Sale Prospectus or the Prospectus shall include
all documents subsequently filed by the Company with the Commission pursuant to the Securities Exchange Act of 1934, as amended (the
&ldquo;<B>Exchange Act</B>&rdquo;), that are deemed to be incorporated by reference therein.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
<I>Representations and Warranties</I>. The Company represents and warrants to and agrees with each of the Underwriters that:</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
The Registration Statement has become effective; no stop order suspending the effectiveness of the Registration Statement is in effect,
and no proceedings for such purpose or pursuant to Section 8A under the Securities Act are pending before or, to the Company&rsquo;s
knowledge, threatened by the Commission.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 13.5pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
(i) Each document, if any, filed, or to be filed pursuant to the Exchange Act and incorporated by reference in the Time of Sale Prospectus
or the Prospectus complied (at the time of filing, or the extent amended prior to the date hereof, on the date amended) or will comply
when so filed in all material respects with the Exchange Act and the applicable rules and regulations of the Commission thereunder, (ii)
the Registration Statement, when it became effective, did not contain and, as amended or supplemented, if applicable, will not, as of
the date of such amendment or supplement, contain any untrue statement of a material fact or omit to state a material fact required to
be stated therein or necessary to make the statements therein not misleading, (iii) the Registration Statement and the Prospectus comply
and, as amended or supplemented, if applicable, as of the date of such amendment or supplement, will comply in all material respects
with the Securities Act and the applicable rules and regulations of the Commission thereunder, (iv) the Time of Sale Prospectus does
not, and at the time of each sale of the Securities in connection with the offering when the Prospectus is not yet available to prospective
purchasers and at the Closing Date (as defined in Section 4), the Time of Sale Prospectus, as then amended or supplemented by the Company,
if applicable, as of the date of such amendment or supplement, will not, contain any untrue statement of a material fact or omit to state
a material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading,
(v) each broadly available road show, if any, when considered together with the Time of Sale Prospectus, does not contain any untrue
statement of a material fact or omit to state a material fact necessary to make the statements therein, in the light of the circumstances
under which they were made, not misleading and (vi) the Prospectus, as of its date, does not contain and, as amended or supplemented,
if applicable, as of the date of such amendment or supplement, will not contain, as of the date of such amendment or supplement or as
of the Closing Date, any untrue statement of a material fact or omit to state a material fact necessary to make the statements therein,
in the light of the circumstances under which they were made, not misleading, except that the representations and warranties set forth
in this paragraph do not apply to statements or omissions in the Registration Statement, the Time of Sale Prospectus or the Prospectus
based upon information relating to any Underwriter furnished to the Company in writing by such Underwriter through the Representative
expressly for use therein, it being understood and agreed that the only such information furnished in writing by the Underwriters through
the Representative consists of the Underwriter Information (as defined below). Each document filed pursuant to the Exchange Act and incorporated
by reference in the Time of Sale Prospectus or the Prospectus complied when so filed, or to the extent it has been amended prior to the
date hereof, as of the date amended, in all material respects with the Exchange Act and the applicable rules and regulations of the Commission
thereunder.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 13.5pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 13.5pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
The Company is not an &ldquo;ineligible issuer&rdquo; in connection with the offering pursuant to Rules 164, 405 and 433 under the Securities
Act. Any free writing prospectus that the Company is required to file pursuant to Rule 433(d) under the Securities Act has been, or will
be, filed with the Commission in accordance with the requirements of the Securities Act and the applicable rules and regulations of the
Commission thereunder. Each free writing prospectus that the Company has filed, or is required to file, pursuant to Rule 433(d) under
the Securities Act or that was prepared by or on behalf of or used or referred to by the Company complies or, if filed after the date
of this Agreement, will comply as of the date of such filing, in all material respects with the requirements of the Securities Act and
the applicable rules and regulations of the Commission thereunder. Except for the free writing prospectuses, if any, identified in <U>Schedule
II</U> hereto, and electronic road shows, if any, each furnished to the Representative before first use, the Company has not prepared,
used or referred to, and will not, without the prior consent of the Representative, prepare, use or refer to, any free writing prospectus.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 13.5pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
The Company has been duly incorporated, is validly existing as a corporation in good standing under the laws of the jurisdiction of its
incorporation, has the corporate power and authority to own or lease its property and to conduct its business as described in each of
the Registration Statement, the Time of Sale Prospectus and the Prospectus and is duly qualified to transact business and is in good
standing in each jurisdiction (to the extent the concept of good standing or an equivalent concept is applicable in such jurisdiction)
in which the conduct of its business or its ownership or leasing of property requires such qualification, except to the extent that the
failure to be so qualified or be in good standing would not, individually or in the aggregate, reasonably be expected to have a material
adverse effect on the Company and its subsidiaries, taken as a whole.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 13.5pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 13.5pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
Each &ldquo;significant subsidiary&rdquo; (as such term is defined in Rule 1-02(w) of Regulation S-X) of the Company has been duly incorporated,
organized or formed, is validly existing as a corporation or other business entity in good standing under the laws of the jurisdiction
of its incorporation, organization or formation (to the extent the concept of good standing or any functional equivalent is applicable
in such jurisdiction), has the corporate or other business entity power and authority to own or lease its property and to conduct its
business as described in each of the Registration Statement, the Time of Sale Prospectus and the Prospectus and is duly qualified to
transact business and is in good standing in each jurisdiction (to the extent the concept of good standing or any functional equivalent
is applicable in such jurisdiction) in which the conduct of its business or its ownership or leasing of property requires such qualification,
except to the extent that the failure to be so qualified or be in good standing would not, individually or in the aggregate, reasonably
be expected to have a material adverse effect on the Company and its subsidiaries, taken as a whole; all of the issued shares of capital
stock or other equity interests of each significant subsidiary have been duly and validly authorized and issued, are fully paid and non-assessable
and are owned directly by the Company, free and clear of all liens, encumbrances, equities or claims, except for such liens, encumbrances,
equities or claims that would not, singly or in the aggregate, reasonably be expected to have a material adverse effect on the Company
and its subsidiaries, taken as a whole.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 13.5pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
This Agreement has been duly authorized, executed and delivered by the Company.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 13.5pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)
The authorized capital stock of the Company conforms in all material respects as to legal matters to the description thereof contained
in each of the Registration Statement, the Time of Sale Prospectus and the Prospectus as of the dates set forth therein.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 13.5pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)
The shares of Common Stock outstanding prior to the issuance of the Securities have been duly authorized and are validly issued, fully
paid and non-assessable.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 13.5pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
The Shares have been duly authorized and, when issued, delivered and paid for in accordance with the terms of this Agreement, will be
validly issued, fully paid and non-assessable, and the issuance of the Shares will not be subject to any preemptive or similar rights.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 13.5pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)
The Pre-Funded Warrants have been duly authorized and, when executed and delivered by the Company, will be valid and binding agreements
of the Company, enforceable against the Company in accordance with their terms, except as the enforcement thereof may be limited by bankruptcy,
insolvency, reorganization, moratorium or other similar laws relating to or affecting the rights and remedies of creditors or by general
equitable principles. The Warrant Shares have been duly authorized and will be reserved for issuance upon exercise of the Pre-Funded
Warrants in a number sufficient to meet the current exercise requirements. The Warrant Shares, when issued and delivered upon exercise
of the Pre-Funded Warrants in accordance therewith, will be validly issued, fully paid and nonassessable, and the issuance of the Warrant
Shares is not subject to any preemptive or similar rights not otherwise validly waived or satisfied.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 13.5pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 13.5pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)
The execution and delivery by the Company of, and the performance by the Company of its obligations under, this Agreement will not contravene
any provision of applicable law or the certificate of incorporation or by-laws of the Company or any agreement or other instrument binding
upon the Company or any of its significant subsidiaries that is material to the Company and its significant subsidiaries, taken as a
whole, or any judgment, order or decree of any governmental body, agency or court having jurisdiction over the Company or any significant
subsidiary, and no consent, approval, authorization or order of, or qualification with, any governmental body, agency or court is required
for the performance by the Company of its obligations under this Agreement, except such as may be required by the securities or Blue
Sky laws of the various states in connection with the offer and sale of the Securities.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 13.5pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l)
There has not occurred any material adverse change, or any development involving a prospective material adverse change, in the condition,
financial or otherwise, or in the earnings, business or operations of the Company and its subsidiaries, taken as a whole, from that set
forth in the Time of Sale Prospectus.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 13.5pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(m)
There are no legal or governmental proceedings pending or, to the knowledge of the Company, threatened to which the Company or any of
its subsidiaries is a party or to which any of the properties of the Company or any of its subsidiaries is subject (i) other than proceedings
accurately described in all material respects in each of the Registration Statement, the Time of Sale Prospectus and the Prospectus and
proceedings that would not, singly or in the aggregate, reasonably be expected to have a material adverse effect on the Company and its
subsidiaries, taken as a whole, or on the power or ability of the Company to perform its obligations under this Agreement or to consummate
the transactions contemplated by each of the Registration Statement, the Time of Sale Prospectus and the Prospectus or (ii) that are
required to be described in the Registration Statement, the Time of Sale Prospectus or the Prospectus and are not so described in all
material respects; and there are no statutes, regulations, contracts or other documents that are required to be described in the Registration
Statement, the Time of Sale Prospectus or the Prospectus or to be filed as exhibits to the Registration Statement that are not described
in all material respects or filed as required.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 13.5pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(n)
Each preliminary prospectus filed as part of the Registration Statement as originally filed or as part of any amendment thereto, or filed
pursuant to Rule 424 under the Securities Act, complied when so filed in all material respects with the Securities Act and the applicable
rules and regulations of the Commission thereunder.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 13.5pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(o)
The Company is not, and after giving effect to the offering and sale of the Securities and the application of the proceeds thereof as
described in each of the Registration Statement, the Time of Sale Prospectus and the Prospectus will not be, required to register as
an &ldquo;investment company&rdquo; as such term is defined in the Investment Company Act of 1940, as amended.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 13.5pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(p)
No material labor dispute with the employees of the Company or any of its subsidiaries exists or, to the knowledge of the Company, is
imminent; and the Company is not aware of any existing, threatened or imminent labor disturbance by the employees of any of its principal
suppliers, manufacturers or contractors that would reasonably be expected have a material adverse effect on the Company and its subsidiaries,
taken as a whole.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 13.5pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 13.5pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(q)
The Company and each of its subsidiaries, taken as a whole, (i) are in compliance with any and all applicable foreign, federal, state
and local laws and regulations relating to the protection of human health and safety, the environment or hazardous or toxic substances
or wastes, pollutants or contaminants (&ldquo;<B>Environmental Laws</B>&rdquo;), (ii) have received all permits, licenses or other approvals
required of them under applicable Environmental Laws to conduct their respective businesses and (iii) are in compliance with all terms
and conditions of any such permit, license or approval, except where such noncompliance with Environmental Laws, failure to receive required
permits, licenses or other approvals or failure to comply with the terms and conditions of such permits, licenses or approvals would
not, individually or in the aggregate, reasonably be expected to have a material adverse effect on the Company and its subsidiaries,
taken as a whole.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 13.5pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(r)
There are no costs or liabilities associated with Environmental Laws (including, without limitation, any capital or operating expenditures
required for clean-up, closure of properties or compliance with Environmental Laws or any permit, license or approval, any related constraints
on operating activities and any potential liabilities to third parties) which would, individually or in the aggregate, reasonably be
expected to have a material adverse effect on the Company and its subsidiaries, taken as a whole.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 13.5pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(s)
Except as have been waived or complied with or as otherwise described in the Time of Sale Prospectus or the Prospectus, there are no
contracts, agreements or understandings between the Company and any person granting such person the right to require the Company to file
a registration statement under the Securities Act with respect to any securities of the Company or to require the Company to include
such securities with the Securities registered pursuant to the Registration Statement.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 13.5pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(t)
(i) None of the Company or any of its subsidiaries or affiliates, or any director, officer, or employee of the Company nor, to the Company&rsquo;s
knowledge, any agent or representative of the Company or of any of its subsidiaries or affiliates, has taken or will take any action
in furtherance of an offer, payment, promise to pay, or authorization or approval of the payment, giving or receipt of money, property,
gifts or anything else of value, directly or indirectly, to any government official (including any officer or employee of a government
or government-owned or controlled entity or of a public international organization, or any person acting in an official capacity for
or on behalf of any of the foregoing, or any political party or party official or candidate for political office) in order to influence
official action, or to any person in violation of any applicable Anti-Corruption Laws (as defined below); (ii) the Company and each of
its subsidiaries and affiliates have conducted their businesses in compliance with all applicable Anti-Corruption Laws and have instituted
and maintained and will continue to maintain policies and procedures reasonably designed to promote and achieve compliance with such
laws and with the representations and warranties contained herein; and (iii) neither the Company nor any of its subsidiaries will use,
directly or indirectly, the proceeds of the offering in furtherance of an offer, payment, promise to pay, or authorization of the payment
or giving of money, or anything else of value, to any person in violation of any applicable Anti-Corruption Laws.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 13.5pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 13.5pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(u)
Neither the Company nor any of its subsidiaries or affiliates, nor any director, officer, or employee thereof, nor, to the Company&rsquo;s
knowledge, any agent or representative of the Company or of any of its subsidiaries or affiliates, has taken or will take any action
in furtherance of an offer, payment, promise to pay, or authorization or approval of the payment, giving or receipt of money, property,
gifts or anything else of value, directly or indirectly, to any person to improperly influence official action by that person for the
benefit of the Company or its subsidiaries or affiliates, or to otherwise secure any improper advantage, or to any person in violation
of (a) the U.S. Foreign Corrupt Practices Act of 1977, (b) the UK Bribery Act 2010, or (c) any other applicable law, regulation, order,
decree or directive having the force of law and relating to bribery or corruption (collectively, the &ldquo;<B>Anti-Corruption Laws</B>&rdquo;).</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 13.5pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)
The operations of the Company and each of its subsidiaries are and have been conducted at all times in compliance with all applicable
anti-money laundering laws, rules, and regulations, including the financial recordkeeping and reporting requirements contained therein,
and including the Bank Secrecy Act of 1970, applicable provisions of the USA PATRIOT Act of 2001, the Money Laundering Control Act of
1986, and the Anti-Money Laundering Act of 2020 (collectively, the &ldquo;<B>Anti-Money Laundering Laws</B>&rdquo;).</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 13.5pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(w)
(i) Neither the Company nor any of its subsidiaries, nor any director, officer, employee thereof, or, to the Company&rsquo;s knowledge,
any, agent, affiliate, or representative of the Company or any of its subsidiaries, is an individual or entity (&ldquo;<B>Person</B>&rdquo;)
that is, or is owned or controlled by one or more Persons that are:</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 13.5pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD STYLE="text-align: left; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(A)</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the subject of any sanctions
  administered or enforced by the United States Government (including the U.S. Department of the Treasury&rsquo;s Office of Foreign Assets
  Control and the U.S. Department of State), the United Nations Security Council, the European Union, His Majesty&rsquo;s Treasury, or
  any other relevant sanctions authority (collectively, &ldquo;<B>Sanctions</B>&rdquo;), or</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(B)</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">located, organized or resident
  in a country or territory that is the subject of comprehensive territorial Sanctions (including, without limitation, the so-called
  Donetsk People&rsquo;s Republic, the so-called Luhansk People&rsquo;s Republic, or any other Covered Region of Ukraine identified pursuant
  to Executive Order 14065, Crimea, Cuba, Iran, and North Korea).</FONT></TD></TR>
</TABLE>


<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 81pt; text-indent: -9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
The Company and each of its subsidiaries (a) have not, since April 24, 2019, engaged in, (b) are not now engaged in, and (c) will not
engage in, any dealings or transactions with any Person, or in any country or territory, that at the time of the dealing or transaction
is or was, or whose government is or was, the subject of Sanctions.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 27pt; text-indent: 0.8in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 27pt; text-align: justify; text-indent: 0.8in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(x)
The Company will not, directly or indirectly, use the proceeds of the offering, or lend, contribute or otherwise make available such
proceeds to any subsidiary, joint venture partner or other Person:</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 13.5pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
to fund or facilitate any activities or business of or with any Person or in any country or territory that, at the time of such funding
or facilitation, is, or whose government is, the subject of Sanctions;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-indent: 0.8in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
to fund or facilitate any money laundering or terrorist financing activities; or</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-indent: 0.8in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
in any other manner that would cause or result in a violation of any Anti-Corruption Laws, Anti-Money Laundering Laws, or Sanctions by
any Person (including any Person participating in the offering, whether as underwriter, advisor, investor or otherwise).</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-indent: 0.8in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(y)
The Company and its subsidiaries have conducted and will conduct their businesses in compliance with the Anti-Corruption Laws, the Anti-Money
Laundering Laws, and Sanctions, and no investigation, inquiry, action, suit or proceeding by or before any court or governmental agency,
authority or body or any arbitrator involving the Company or any of its subsidiaries with respect to the Anti-Corruption Laws, the Anti-Money
Laundering Laws, or Sanctions is pending or, to the knowledge of the Company, threatened. The Company and its subsidiaries and affiliates
have instituted and maintained and will continue to maintain policies and procedures reasonably designed to promote and achieve compliance
with the Anti-Corruption Laws, the Anti-Money Laundering Laws, Sanctions, and with the representations and warranties contained herein.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 13.5pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(z)
(i) The Company and its subsidiaries own or have a valid license to use any and all patents, inventions, copyrights, copyrightable works,
licenses, know how (including trade secrets and other unpatented and/or unpatentable proprietary or confidential information, systems
or procedures), software, domain names, trademarks, service marks, trade names and other source indicators and all other worldwide intellectual
property and proprietary rights (including all registrations and applications for registration of, and all goodwill associated with,
any of the foregoing) (collectively, &ldquo;<B>Intellectual Property Rights</B>&rdquo;) used in, held for use in or reasonably necessary
to the conduct of their respective businesses as now conducted by them, and as proposed to be conducted in the Registration Statement,
the Time of Sale Prospectus and the Prospectus; (ii) the Intellectual Property Rights owned and exclusively licensed by the Company and
its subsidiaries are, to the Company&rsquo;s knowledge, valid, subsisting and enforceable, and there is no pending or, to the Company&rsquo;s
knowledge, threatened action, suit, proceeding or claim by others challenging the validity, scope or enforceability of, or any rights
of the Company or any of its subsidiaries in, any such Intellectual Property Rights; (iii) neither the Company nor any of its subsidiaries
has received any notice or other threat alleging, or is a party to any action, suit, investigation or proceeding involving any allegation
of, any infringement, misappropriation or other violation of any Intellectual Property Rights; (iv) to the Company&rsquo;s knowledge,
no third party is infringing, misappropriating or otherwise violating, or has infringed, misappropriated or otherwise violated, any Intellectual
Property Rights owned or exclusively licensed by the Company or any of its subsidiaries; (v) to the Company&rsquo;s knowledge, neither
the Company nor any of its subsidiaries, nor the conduct of their respective businesses, infringes, misappropriates or otherwise violates,
or has infringed, misappropriated or otherwise violated, any Intellectual Property Rights; (vi) all employees and contractors engaged
in the development of Intellectual Property Rights on behalf of the Company or any subsidiary of the Company have executed an invention
assignment agreement whereby such employees and contractors presently assign all of their right, title and interest in and to such Intellectual
Property Rights to the Company or its applicable subsidiary, and to the Company&rsquo;s knowledge no such agreement has been breached
or violated; and (vii) the Company and its subsidiaries use, and have used, commercially reasonable efforts to appropriately maintain
the confidentiality of all trade secrets and other confidential information of the Company and its subsidiaries, and no such trade secrets
or other confidential information have been disclosed other than to employees, representatives and agents of the Company or any of its
subsidiaries, all of whom are bound by written confidentiality agreements.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 13.5pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 13.5pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(aa)
Except as would not, individually or in the aggregate, reasonably be expected to have a material adverse effect on the Company and its
subsidiaries, taken as a whole, (i) the Company and each of its subsidiaries have complied and are presently in compliance with all internal
and external privacy policies and notices, contractual obligations, industry standards, applicable laws, statutes, judgments, orders,
rules and regulations of any court or arbitrator or other governmental or regulatory authority and any other legal obligations, in each
case, relating to the collection, use, transfer, import, export, storage, protection, disposal, disclosure and other processing by the
Company or any of its subsidiaries of personal, personally identifiable, household, sensitive, confidential or regulated data or information
(&ldquo;<B>Data Security Obligations</B>&rdquo;, and such data and information, &ldquo;<B>Personal Data</B>&rdquo;); (ii) the Company
and its subsidiaries have not received any written notification of or written complaint regarding and are unaware of any other facts
that, individually or in the aggregate, would reasonably indicate non-compliance with any Data Security Obligation by the Company or
any of its subsidiaries; and (iii) there is no action, suit, investigation or proceeding by or before any court or governmental agency,
authority or body pending or, to the Company&rsquo;s knowledge, threatened, against the Company or any of its subsidiaries alleging non-compliance
with any Data Security Obligation by the Company or any of its subsidiaries.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 13.5pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(bb)
Except as would not, individually or in the aggregate, reasonably be expected to have a material adverse effect on the Company and its
subsidiaries, taken as a whole, the Company&rsquo;s and its subsidiaries&rsquo; respective information technology assets and equipment,
computers, systems, networks, hardware, software, websites, applications, technology, data and databases (including Personal Data and
the data and information of their respective customers, employees, suppliers, vendors and any third-party data maintained, stored or
otherwise processed by or on behalf of the Company and its subsidiaries) used in connection with the operation of the Company&rsquo;s
and its subsidiaries&rsquo; respective businesses (&ldquo;<B>IT Systems and Data</B>&rdquo;) are adequate for, and operate and perform
in all material respects as required in connection with, the operation of the business of the Company and its subsidiaries as currently
conducted, and, to the Company&rsquo;s knowledge, the IT Systems and Data are free and clear of all bugs, errors, defects, Trojan horses,
time bombs, malware and other corruptants. The Company and each of its subsidiaries have taken all technical, physical, administrative
and organizational measures necessary to protect the IT Systems and Data, and without limiting the foregoing, the Company and its subsidiaries
have used reasonable efforts to establish and maintain, and have established, maintained, implemented and complied with, all reasonable
information technology, information security, cybersecurity and data protection controls, policies and procedures, including oversight,
access controls, encryption, technological and physical safeguards and business continuity/disaster recovery and security plans, consistent
with industry standards and practices, that are designed to protect against and prevent breach, destruction, loss, unauthorized distribution,
use, access, disablement, misappropriation or modification, or other compromise or misuse of or relating to any IT Systems and Data (&ldquo;<B>Breach</B>&rdquo;).
There has been no such Breach, and the Company and its subsidiaries have not been notified of and have no knowledge of any event or condition
that would reasonably be expected to result in, any such Breach.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 13.5pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(cc)
The Company and its subsidiaries possess all certificates, authorizations and permits issued by the appropriate federal, state or foreign
regulatory authorities necessary to conduct their respective businesses, and neither the Company nor any of its subsidiaries has received
any notice of proceedings relating to the revocation or modification of any such certificate, authorization or permit which, singly or
in the aggregate, if the subject of an unfavorable decision, ruling or finding, would have a material adverse effect on the Company and
its subsidiaries, taken as a whole, except as described in the Registration Statement, the Time of Sale Prospectus and Prospectus.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 13.5pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 13.5pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(dd)
The Company and its subsidiaries have operated at all times and are currently in compliance with all applicable statutes, rules, regulations
and policies of the U.S. Food and Drug Administration (the &ldquo;<B>FDA</B>&rdquo;) and applicable foreign regulatory authorities, including
the European Medicines Agency and the UK Medicines &amp; Healthcare products Regulatory Agency (collectively, the &ldquo;<B>Regulatory
Authorities</B>&rdquo;), except where failure to be in compliance would not reasonably be expected to have a material adverse effect
on the Company and its subsidiaries, taken as a whole, including, without limitation the following, as applicable: (i) the Federal Food,
Drug, and Cosmetic Act and the regulations promulgated thereunder; (ii) all applicable federal, state, local and foreign health care
laws, including, without limitation, the U.S. Anti-Kickback Statute (42 U.S.C. Section 1320a-7b(b)), the Civil Monetary Penalties Law
(42 U.S.C. &sect; 1320a-7a), the U.S. Civil False Claims Act (31 U.S.C. Section 3729 et seq.), all applicable federal, state, local and
all foreign criminal laws relating to health care fraud and abuse, including but not limited to the U.S. False Statements Law (42 U.S.C.
Section 1320a-7b(a)), 18 U.S.C. Sections 286 and 287, and the health care fraud criminal provisions under the U.S. Health Insurance Portability
and Accountability Act of 1996 (&ldquo;<B>HIPAA</B>&rdquo;) (42 U.S.C. Section 1320d et seq.), the exclusion laws, the statutes, regulations
and directives of applicable government funded or sponsored healthcare programs, and the regulations promulgated pursuant to such statutes;
(iii) the Standards for Privacy of Individually Identifiable Health Information, the Security Standards, and the Standards for Electronic
Transactions and Code Sets promulgated under HIPAA, the Health Information Technology for Economic and Clinical Health Act (42 U.S.C.
Section 17921 et seq.), and the regulations promulgated thereunder and any state or non-U.S. counterpart thereof or any other law or
regulation the purpose of which is to protect the privacy of individuals or prescribers; (iv) the Patient Protection and Affordable Care
Act of 2010, as amended by the Health Care and Education Reconciliation Act of 2010, the regulations promulgated thereunder; (v) the
U.S. Controlled Substances Act (21 U.S.C. Section 801 et seq.); (vi) the Clinical Laboratories Improvement Act of 1967, as amended);
(vii) licensure, quality, safety and accreditation requirements under applicable federal, state, local or foreign laws or regulatory
bodies; and (viii) all other local, state, federal, national, supranational and foreign laws, relating to the regulation of the Company
or its subsidiaries and the ownership, testing, development, manufacture, packaging, processing, use, distribution, marketing, labeling,
promotion, sale, offer for sale, storage, import, export or disposal of any product under development, manufactured or distributed by
the Company (clauses (i) through (vii), collectively, &ldquo;<B>Health Care Laws</B>&rdquo;).</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 13.5pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ee)
(i) The studies, tests and preclinical and clinical trials conducted by the Company, to the knowledge of the Company, any studies, tests
and preclinical and clinical trials conducted on behalf of or sponsored by the Company or its subsidiaries or in which the Company or
its subsidiaries have participated, were conducted and are being conducted in accordance with (A) standard medical and experimental protocols,
procedures and controls pursuant to accepted professional scientific research standards and procedures and (B) all applicable Health
Care Laws, rules and regulations of the Regulatory Authorities and current Good Clinical Practices and Good Laboratory Practices; (ii)
the descriptions of the results of such studies and trials contained in the Registration Statement, the Time of Sale Prospectus and the
Prospectus are accurate and complete in all material respects and fairly present the data derived from such trials and studies; (iii)
the Company has no knowledge of any other studies or trials not described in the Registration Statement, the Time of Sale Prospectus
and the Prospectus, the results of which the Company reasonably believes are inconsistent with or call into question the results described
or referred to in the Registration Statement, the Time of Sale Prospectus and the Prospectus; (iv) the Company has provided the Representative
with all material substantive written notices, correspondence and summaries of all other material communications provided to the Company
or its subsidiaries from the Regulatory Authorities; and (v) neither the Company nor any of its subsidiaries have received any written
notices, correspondence or other communications from any Regulatory Authority or any other governmental entity requiring or threatening
the termination, modification or suspension of any studies or trials that are described in the Registration Statement, the Time of Sale
Prospectus and the Prospectus or the results of which are referred to in the Registration Statement, the Time of Sale Prospectus and
the Prospectus, and, to the Company&rsquo;s knowledge, there are no reasonable grounds for the same.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 13.5pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 13.5pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ff)
(i) The Company and its subsidiaries have filed, obtained, maintained or submitted all material reports, documents, forms, notices, applications,
records, claims, submissions and supplements or amendments as required by any applicable Health Care Laws, and all such reports, documents,
forms, notices, applications, records, claims, submissions and supplements or amendments were, in all material respects, timely, complete,
accurate and not misleading on the date filed (or were corrected or supplemented by a subsequent submission); (ii) neither the Company
nor its subsidiaries have received written notice of any claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration
or other action from any court or arbitrator or Regulatory Authority, other governmental entity or third party alleging that any Company,
subsidiary, or product operation or activity is in violation of any Health Care Laws, including, without limitation, any FDA Form 483,
notice of adverse finding, warning letter, untitled letter or other correspondence or notice from the FDA or any other Regulatory Authority
or governmental entity, nor, to the Company&rsquo;s knowledge, is any such claim, action, suit, proceeding, hearing, enforcement, investigation,
arbitration or other action threatened or under consideration by the FDA or any other Regulatory Authority; (iii) neither the Company
nor its subsidiaries are a party to any corporate integrity agreements, monitoring agreements, consent decrees, settlement orders, or
similar agreements with or imposed by any Regulatory Authority or other governmental entity; and (iv) neither the Company, its subsidiaries
nor any of their respective employees, officers or directors has been excluded, suspended or debarred from participation in any U.S.
federal health care program or human clinical research or, to the knowledge of the Company, is subject to an inquiry, investigation,
proceeding or other similar action by a Regulatory Authority or other governmental entity that could reasonably be expected to result
in debarment, suspension, or exclusion.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 13.5pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(gg)
The Company and each of its subsidiaries are insured by insurers of recognized financial responsibility against such losses and risks
and in such amounts as, in the reasonable judgment of the Company, are prudent and customary in the businesses in which they are engaged;
neither the Company nor any of its subsidiaries has been refused any insurance coverage sought or applied for; and neither the Company
nor any of its subsidiaries has any reason to believe that it will not be able to renew its existing insurance coverage as and when such
coverage expires or to obtain similar coverage from similar insurers as may be necessary to continue its business at a cost that would
not, singly or in the aggregate, reasonably be expected to have a material adverse effect on the Company and its subsidiaries, taken
as a whole.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 13.5pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(hh)
The Company and each of its subsidiaries have filed all federal, state, local and foreign tax returns required to be filed through the
date of this Agreement or have requested extensions thereof (except where the failure to file would not, singly or in the aggregate,
have a material adverse effect on the Company and its subsidiaries, taken as a whole) and have paid all taxes required to be paid thereon
(except for cases in which the failure to file or pay would not, singly or in the aggregate, have a material adverse effect on the Company
and its subsidiaries, taken as a whole, or, except as currently being contested in good faith and for which reserves required by generally
accepted accounting principles (&ldquo;<B>U.S. GAAP</B>&rdquo;) have been created in the financial statements of the Company), and no
tax deficiency has been determined adversely to the Company or any of its subsidiaries which, singly or in the aggregate, has had (nor
does the Company nor any of its subsidiaries have any notice or knowledge of any tax deficiency which could reasonably be expected to
be determined adversely to the Company or its subsidiaries and which could reasonably be expected to have) a material adverse effect
on the Company and its subsidiaries, taken as a whole.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 13.5pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 13.5pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
The financial statements included or incorporated by reference in each of the Registration Statement, the Time of Sale Prospectus and
the Prospectus, together with the related schedules and notes thereto, comply as to form in all material respects with the applicable
accounting requirements of the Securities Act and present fairly in all material respects the consolidated financial position of the
Company and its consolidated subsidiaries as of the dates shown and its results of operations and cash flows for the periods shown, and
such financial statements have been prepared in conformity with U.S. GAAP applied on a consistent basis throughout the periods covered
thereby except for any normal year-end adjustments in the Company&rsquo;s quarterly financial statements. The other financial information
of the Company and its consolidated subsidiaries included in each of the Registration Statement, the Time of Sale Prospectus and the
Prospectus has been derived from the accounting records of the Company and its consolidated subsidiaries and presents fairly in all material
respects the information shown thereby. The statistical, industry-related and market-related data included in each of the Registration
Statement, the Time of Sale Prospectus and the Prospectus are based on or derived from sources which the Company reasonably and in good
faith believes are reliable and accurate and such data is consistent with the sources from which they are derived, in each case in all
material respects and, to the extent required, the Company has obtained the written consent to the use of such data from such sources.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 13.5pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(jj)
Crowe LLP and KMJ Corbin &amp; Company LLP, who have each certified certain financial statements of the Company and its subsidiaries
and delivered certain reports with respect to the audited consolidated financial statements and schedules filed with the Commission as
part of the Registration Statement and included in each of the Registration Statement, the Time of Sale Prospectus and the Prospectus,
are (or were at the time of service) independent registered public accounting firms with respect to the Company within the meaning of
the Securities Act and the applicable rules and regulations thereunder adopted by the Commission and the Public Company Accounting Oversight
Board (United States).</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 13.5pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(kk)
The Company and each of its subsidiaries maintain a system of internal accounting controls sufficient to provide reasonable assurance
that (i) transactions are executed in accordance with management&rsquo;s general or specific authorizations; (ii) transactions are recorded
as necessary to permit preparation of financial statements in conformity with U.S. GAAP and to maintain asset accountability; (iii) access
to assets is permitted only in accordance with management&rsquo;s general or specific authorization; (iv) the recorded accountability
for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences;
and (v) the interactive data in eXtensible Business Reporting Language included or incorporated by reference in the Registration Statement
is accurate. Since the end of the Company&rsquo;s most recent audited fiscal year, except as described in the Registration Statement,
the Time of Sale Prospectus and the Prospectus, there has been (i) no material weakness in the Company&rsquo;s internal control over
financial reporting (whether or not remediated) and (ii) no change in the Company&rsquo;s internal control over financial reporting that
has materially affected, or is reasonably likely to materially affect, the Company&rsquo;s internal control over financial reporting.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 13.5pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 13.5pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ll)
The Company maintains a system of disclosure controls and procedures (as such term is defined in Rule 13a-15(e) under the Exchange Act)
that are designed to ensure that information required to be disclosed by the Company in reports that it files or submits under the Exchange
Act is recorded, processed, summarized and reported within the time periods specified in the Commission&rsquo;s rules and forms, including
controls and procedures designed to ensure that such information is accumulated and communicated to the Company&rsquo;s management as
appropriate to allow timely decisions regarding required disclosure. The Company has carried out evaluations of the effectiveness of
its disclosure controls and procedures as required by Rule 13a-15 of the Exchange Act and such disclosure controls and procedures were
effective as of the end of the Company&rsquo;s most recently completed fiscal quarter, except as described in the Registration Statement,
the Time of Sale Prospectus and the Prospectus.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 13.5pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(mm)
The interactive data in eXtensible Business Reporting Language included or incorporated by reference in the Registration Statement fairly
presents the information called for in all material respects and has been prepared in accordance with the Commission&rsquo;s rules and
guidelines applicable thereto.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(nn)
From the time of the submission of the Registration Statement to the Commission through the date hereof, the Company has been and is
an &ldquo;emerging growth company,&rdquo; as defined in Section 2(a) of the Securities Act (an &ldquo;<B>Emerging Growth Company</B>&rdquo;).</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(oo)
The Company (i) has not alone engaged in any Testing-the-Waters Communication with any person and (ii) has not authorized anyone other
than <FONT STYLE="letter-spacing: -0.15pt">the Representative </FONT>to engage in Testing-the-Waters Communications. The Company reconfirms
that <FONT STYLE="letter-spacing: -0.15pt">the Representative </FONT>has been authorized to act on its behalf in undertaking Testing-the-Waters
Communications. The Company has not distributed any Testing-the-Waters Communication that is a written communication within the meaning
of Rule 405 under the Securities Act. &ldquo;<B>Testing-the-Waters Communication</B>&rdquo; means any communication with potential investors
undertaken in reliance on Section 5(d) or Rule 163B of the Securities Act.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(pp)
As of the time of each sale of the Securities in connection with the offering when the <FONT STYLE="letter-spacing: -0.15pt">Prospectus</FONT>
is not yet available to prospective purchasers, none of (A) the Time of Sale Prospectus, (B) any free writing prospectus, when considered
together with the Time of Sale Prospectus, and (C) any individual Testing-the-Waters Communication, when considered together with the
Time of Sale Prospectus, included, includes or will include an untrue statement of a material fact or omitted, omits or will omit to
state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made,
not misleading.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(qq)
Neither the <FONT STYLE="letter-spacing: -0.15pt">Company</FONT> nor any of its subsidiaries has any securities rated by any &ldquo;nationally
recognized statistical rating organization,&rdquo; as such term is defined in Section 3(a)(62) of the Exchange Act.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(rr)
Neither <FONT STYLE="letter-spacing: -0.15pt">the</FONT> Company nor any of its subsidiaries is or shall become a &ldquo;covered foreign
person,&rdquo; as that term is used in the regulations administered and enforced by the U.S. Treasury Department under U.S. Executive
Order 14105 and codified at 31 C.F.R. &sect; 850.101 et seq. (the &ldquo;<B>Outbound Investment Rules</B>&rdquo;). Neither the Company
nor any of its subsidiaries currently engages, directly or indirectly, in (i) a &ldquo;covered activity&rdquo; or a &ldquo;covered transaction,&rdquo;
as each such term is defined in the Outbound Investment Rules, (ii) any activity or transaction that would constitute a &ldquo;covered
activity&rdquo; or a &ldquo;covered transaction,&rdquo; as each such term is defined in the Outbound Investment Rules, if the Company
were a &ldquo;U.S. Person&rdquo; (as defined below), or (iii) any other activity that would cause any Underwriter or any of its affiliates
to be in violation of the Outbound Investment Rules or cause any Underwriter or any of its affiliates to be legally prohibited by the
Outbound Investment Rules from performing under this Agreement. For purposes of this paragraph, a &ldquo;<B>U.S. Person</B>&rdquo; means
any United States citizen, lawful permanent resident, entity organized under the laws of the United States or any jurisdiction within
the United States, including any foreign branch of any such entity, or any person in the United States.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
<I>Agreements to Sell and Purchase. </I>The Company hereby agrees to sell to the several Underwriters, and each Underwriter, upon the
basis of the representations and warranties herein contained, but subject to the terms and conditions hereinafter stated, agrees, severally
and not jointly, to purchase from the Company the respective numbers of Securities set forth in <U>Schedule I</U> hereto opposite its
name. The purchase price per Share to be paid by the several Underwriters to the company shall be $4.794 a share (the &ldquo;<B>Share
Purchase Price</B>&rdquo;) and the purchase price per Pre-Funded Warrant to be paid by the several Underwriters to the Company will equal
the Share Purchase Price minus $0.01 (the &ldquo;<B>Warrant Purchase Price</B>&rdquo;).</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
<I>Terms of Public Offering</I>. The Company is advised by the Representative that the Underwriters propose to make a public offering
of their respective portions of the Securities as soon after the Registration Statement and this Agreement have become effective as in
the Representative&rsquo;s judgment is advisable. The Company is further advised by Morgan Stanley that (i) the Shares are to be offered
to the public initially at $5.10 a share (the &ldquo;<B>Public Offering Price</B>&rdquo;) and to certain dealers selected by the Representative
at a price that represents a concession not in excess of $0.1836 a share under the Public Offering Price, and that any Underwriter may
allow and (ii) the Pre-Funded Warrants are to be offered to the public initially at $5.09 per warrant (the &ldquo;Public Offering Price
per Warrant&rdquo;) and to certain dealers selected by the Representative at a price that represents a concession not in excess of 0.1836
per warrant under the Public Offering Price per Warrant.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding
the foregoing, the Company and the Representative shall instruct purchasers of the Pre-Funded Warrants in the public offering to make
payment for the Pre-Funded Warrants on the Closing Date to the Company by wire transfer in immediately available funds to the account
specified by the Company at a purchase price of $5.09 per Pre-Funded Warrant in lieu of payment by the Underwriters for such Warrants,
and the Company shall deliver such Warrants to such purchasers on the Closing Date in definitive form against such payment, in lieu of
the Company&rsquo;s obligation to deliver such Warrants to the Underwriters; provided that the Company shall promptly (but in no event
later than the Closing Date) pay $0.306 per such Pre-Funded Warrant to the Underwriters by wire transfer in immediately available funds
to the account specified by the Representative.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event that the purchasers of the Warrants in the public offering fail to make payment to the Company for all or part of the Warrants
on the Closing Date, the Representative may elect, by written notice to the Company, to receive shares of Common Stock in lieu of all
or a portion of such Warrants to be delivered to the Underwriters under this Agreement.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.
<I>Payment and Delivery. </I>Payment for the Securities shall be made to the Company in Federal or other funds immediately available
in New York City against delivery of such Securities for the respective accounts of the several Underwriters at 10:00 a.m., New York
City time, on December 9, 2025, or at such other time on the same or such other date, not later than December 16, 2025, as shall be designated
in writing by the Representative. The time and date of such payment are hereinafter referred to as the &ldquo;<B>Closing Date</B>.&rdquo;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Securities shall be registered in such names and in such denominations as the Representative shall request not later than one full business
day prior to the Closing Date. The Securities shall be delivered to the Representative on the Closing Date for the respective accounts
of the several Underwriters, with any transfer taxes payable in connection with the transfer of the Securities to the Underwriters duly
paid, against payment of the Purchase Price and the Warrant Purchase Price therefor. The Warrants will be made available for inspection
by the Representative on the business day prior to the Closing Date.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.
<I>Conditions to the Underwriters&rsquo; Obligations</I>. The obligations of the Company to sell the Securities to the Underwriters and
the several obligations of the Underwriters to purchase and pay for the Securities on the Closing Date are subject to the condition that
the Registration Statement shall remain effective as of the date hereof.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
several obligations of the Underwriters are subject to the following further conditions:</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0.25in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
Subsequent to the execution and delivery of this Agreement and prior to the Closing Date:</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 13.5pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
no order suspending the effectiveness of the Registration Statement shall be in effect, and no proceeding for such purpose or pursuant
to Section 8A under the Securities Act shall be pending before or, to the Company&rsquo;s knowledge, threatened by the Commission; and</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-indent: 0.8in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
there shall not have occurred any change, or any development involving a prospective change, in the condition, financial or otherwise,
or in the earnings, business or operations of the Company and its subsidiaries, taken as a whole, from that set forth in the Time of
Sale Prospectus that, in the judgment of the Representative, is material and adverse and that makes it, in the judgment of the Representative,
impracticable to market the Securities on the terms and in the manner contemplated in the Time of Sale Prospectus.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-indent: 0.8in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
The Underwriters shall have received on the Closing Date a certificate, dated the Closing Date and signed by an executive officer of
the Company, to the effect set forth in Sections 5(a)(i) and 5(a)(ii) above and to the effect that the representations and warranties
of the Company contained in this Agreement are true and correct as of the Closing Date and that the Company has complied with all of
the agreements and satisfied all of the conditions on its part to be performed or satisfied hereunder on or before the Closing Date.
The officer signing and delivering such certificate may rely upon the best of his or her knowledge as to proceedings threatened.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 13.5pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
The Underwriters shall have received on the Closing Date an opinion and negative assurance letter of Loev Law Firm, PC, outside counsel
for the Company, dated the Closing Date, in form and substance reasonably satisfactory to the Representative.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 13.5pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
The Underwriters shall have received on the Closing Date an opinion of Dickinson Wright LLP, outside intellectual property counsel for
the Company, dated the Closing Date, in form and substance reasonably satisfactory to the Representative.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 13.5pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
The Underwriters shall have received on the Closing Date an opinion and negative assurance letter of Davis Polk &amp; Wardwell LLP, counsel
for the Underwriters, dated the Closing Date, in form and substance reasonably satisfactory to the Representative.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 13.5pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
respect to Section &lrm;5&lrm;(c) above, Loev Law Firm, PC may state that their opinions and beliefs are based upon their participation
in the preparation of the Time of Sale Prospectus and the Prospectus and any amendments or supplements thereto and review and discussion
of the contents thereof, but are without independent check or verification, except as specified. With respect to Section &lrm;5(e) above,
Davis Polk &amp; Wardwell LLP may state that their opinions and beliefs are based upon their participation in the preparation of the
Time of Sale Prospectus and the Prospectus and any amendments or supplements thereto (other than the documents incorporated by reference)
and upon review and discussion of the contents thereof (including documents incorporated by reference), but are without independent check
or verification, except as specified.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
The Underwriters shall have received, on each of the date hereof and the Closing Date, a letter dated the date hereof or the Closing
Date, as the case may be, in form and substance satisfactory to the Representative, from Crowe LLP, independent public accountants, containing
statements and information of the type ordinarily included in accountants&rsquo; &ldquo;comfort letters&rdquo; to underwriters with respect
to the financial statements and certain financial information contained in the Registration Statement, the Time of Sale Prospectus and
the Prospectus; <I>provided</I> that the letter delivered on the Closing Date shall use a &ldquo;cut-off date&rdquo; not earlier than
the date hereof.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 13.5pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)
The Underwriters shall have received, on each of the date hereof and the Closing Date, a letter dated the date hereof or the Closing
Date, as the case may be, in form and substance satisfactory to the Representative, from KMJ Corbin &amp; Company LLP, independent public
accountants, containing statements and information of the type ordinarily included in accountants&rsquo; &ldquo;comfort letters&rdquo;
to underwriters with respect to the financial statements and certain financial information contained in the Registration Statement, the
Time of Sale Prospectus and the Prospectus; <I>provided</I> that the letter delivered on the Closing Date shall use a &ldquo;cut-off
date&rdquo; not earlier than the date hereof.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 13.5pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)
The &ldquo;lock-up&rdquo; agreements, each substantially in the form of <U>Exhibit A</U> hereto, between the Representative and certain
officers and directors of the Company relating to restrictions on sales and certain other dispositions of shares of Common Stock or certain
other securities, delivered to the Representative on or before the date hereof, shall be in full force and effect on the Closing Date.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 13.5pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
Such other documents as the Representative may reasonably request, including with respect to the good standing of the Company and its
subsidiaries, the due authorization and issuance of the Securities and other matters related to the issuance of the Securities.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 13.5pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.
<I>Covenants of the Company</I>. The Company covenants with each Underwriter as follows:</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
To furnish to the Representative, without charge, two signed copies of the Registration Statement (including exhibits thereto and documents
incorporated by reference) and for delivery to each other Underwriter a conformed copy of the Registration Statement (without exhibits
thereto but including documents incorporated by reference) and to furnish to the Representative in New York City, without charge, prior
to 10:00 a.m. New York City time on the business day next succeeding the date of this Agreement and during the period mentioned in Section
6(e) or 6(f) below, as many copies of the Time of Sale Prospectus, the Prospectus, any documents incorporated by reference therein and
any supplements and amendments thereto or to the Registration Statement as the Representative may reasonably request.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 13.5pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 13.5pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Before amending or supplementing the Registration Statement, the Time of Sale Prospectus or the Prospectus, to furnish to the Representative
a copy of each such proposed amendment or supplement and not to file any such proposed amendment or supplement to which the Representative
reasonably objects, and to file with the Commission within the applicable period specified in Rule 424(b) under the Securities Act any
prospectus required to be filed pursuant to such Rule.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 13.5pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
To furnish to the Representative a copy of each proposed free writing prospectus to be prepared by or on behalf of, used by, or referred
to by the Company and not to use or refer to any proposed free writing prospectus to which the Representative reasonably objects.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 13.5pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
Not to take any action that would result in an Underwriter or the Company being required to file with the Commission pursuant to Rule
433(d) under the Securities Act a free writing prospectus prepared by or on behalf of the Underwriter that the Underwriter otherwise
would not have been required to file thereunder.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 13.5pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
If the Time of Sale Prospectus is being used to solicit offers to buy the Securities at a time when the Prospectus is not yet available
to prospective purchasers and any event shall occur or condition exist as a result of which it is necessary to amend or supplement the
Time of Sale Prospectus in order to make the statements therein, in the light of the circumstances, not misleading, or if any event shall
occur or condition exist as a result of which the Time of Sale Prospectus conflicts with the information contained in the Registration
Statement then on file, or if, in the reasonable opinion of counsel for the Underwriters, it is necessary to amend or supplement the
Time of Sale Prospectus to comply with applicable law, forthwith to prepare, file with the Commission and furnish, at its own expense,
to the Underwriters and to any dealer upon request, either amendments or supplements to the Time of Sale Prospectus so that the statements
in the Time of Sale Prospectus as so amended or supplemented will not, in the light of the circumstances when the Time of Sale Prospectus
is delivered to a prospective purchaser, be misleading or so that the Time of Sale Prospectus, as amended or supplemented, will no longer
conflict with the Registration Statement, or so that the Time of Sale Prospectus, as amended or supplemented, will comply with applicable
law.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 13.5pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
If, during such period after the first date of the public offering of the Securities as in the reasonable opinion of counsel for the
Underwriters the Prospectus (or in lieu thereof the notice referred to in Rule 173(a) of the Securities Act) is required by law to be
delivered in connection with sales by an Underwriter or dealer, any event shall occur or condition exist as a result of which it is necessary
to amend or supplement the Prospectus in order to make the statements therein, in the light of the circumstances when the Prospectus
(or in lieu thereof the notice referred to in Rule 173(a) of the Securities Act) is delivered to a purchaser, not misleading, or if,
in the reasonable opinion of counsel for the Underwriters, it is necessary to amend or supplement the Prospectus to comply with applicable
law, forthwith to prepare, file with the Commission and furnish, at its own expense, to the Underwriters and to the dealers (whose names
and addresses the Representative will furnish to the Company) to which Securities may have been sold by the Representative on behalf
of the Underwriters and to any other dealers upon request, either amendments or supplements to the Prospectus so that the statements
in the Prospectus as so amended or supplemented will not, in the light of the circumstances when the Prospectus (or in lieu thereof the
notice referred to in Rule 173(a) of the Securities Act) is delivered to a purchaser, be misleading or so that the Prospectus, as amended
or supplemented, will comply with applicable law.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 13.5pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 13.5pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)
To endeavor to qualify the Securities for offer and sale under the securities or Blue Sky laws of such jurisdictions as the Representative
shall reasonably request; provided, however, that nothing contained herein shall require the Company to qualify as a foreign corporation
or other entity or as a dealer in securities in any jurisdiction where it would not otherwise be required to so qualify or file any general
consent to service of process in any such jurisdiction or to subject itself to taxation in any such jurisdiction of it is not otherwise
so subject.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 13.5pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)
To make generally available to the Company&rsquo;s securityholders and to the Representative as soon as practicable, which may be satisfied
by filing with the Commission&rsquo;s Electronic Data Gathering Analysis and Retrieval System, an earnings statement covering a period
of at least twelve months beginning with the first fiscal quarter of the Company occurring after the date of this Agreement which shall
satisfy the provisions of Section 11(a) of the Securities Act and the rules and regulations of the Commission thereunder.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 13.5pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
Whether or not the transactions contemplated in this Agreement are consummated or this Agreement is terminated, to pay or cause to be
paid all expenses incident to the performance of its obligations under this Agreement, including: (i) the fees, disbursements and expenses
of the Company&rsquo;s counsel and the Company&rsquo;s accountants in connection with the registration and delivery of the Securities
under the Securities Act and all other fees or expenses in connection with the preparation and filing of the Registration Statement,
any preliminary prospectus, the Time of Sale Prospectus, the Prospectus, any free writing prospectus prepared by or on behalf of, used
by, or referred to by the Company and amendments and supplements to any of the foregoing, including all printing costs associated therewith,
and the mailing and delivering of copies thereof to the Underwriters and dealers, in the quantities hereinabove specified, (ii) all costs
and expenses related to the transfer and delivery of the Securities to the Underwriters, including any transfer or other taxes payable
thereon, (iii) the cost of printing or producing any Blue Sky or Legal Investment memorandum in connection with the offer and sale of
the Securities under state securities laws and all expenses in connection with the qualification of the Securities for offer and sale
under state securities laws as provided in Section 6(g) hereof, including filing fees and the reasonable fees and disbursements of counsel
for the Underwriters in connection with such qualification and in connection with the Blue Sky or Legal Investment memorandum, (iv) all
filing fees and the reasonable fees and disbursements of counsel to the Underwriters incurred in connection with the review and qualification
of the offering of the Securities by the Financial Industry Regulatory Authority, (v) all costs and expenses incident to listing the
Securities on the Nasdaq Capital Market, (vi) the cost of printing certificates representing the Securities, (vii) the costs and charges
of any transfer agent, registrar or depositary, (viii) the costs and expenses of the Company relating to investor presentations on any
&ldquo;road show&rdquo; undertaken in connection with the marketing of the offering of the Securities, including, without limitation,
expenses associated with the preparation or dissemination of any electronic road show, expenses associated with the production of road
show slides and graphics, fees and expenses of any consultants engaged in connection with the road show presentations with the prior
approval of the Company, travel and lodging expenses of the representatives and officers of the Company and any such consultants, (ix)
the document production charges and expenses associated with printing this Agreement and (x) all other costs and expenses incident to
the performance of the obligations of the Company hereunder for which provision is not otherwise made in this Section 6. It is understood,
however, that except as provided in this Section 6, Section 8 entitled &ldquo;Indemnity and Contribution&rdquo; and the last paragraph
of Section 10 below, the Underwriters will pay all of their costs and expenses, including fees and disbursements of their counsel, stock
transfer taxes payable on resale of any of the Securities by them and any advertising expenses connected with any offers they may make.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 13.5pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 13.5pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)
The Company will promptly notify the Representative if the Company ceases to be an Emerging Growth Company at any time prior to the later
of (i) completion of the distribution of the Securities within the meaning of the Securities Act and (ii) completion of the Restricted
Period (as defined in this Section 6).</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 13.5pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)
If at any time following the distribution of any Testing-the-Waters Communication that is a written communication within the meaning
of Rule 405 under the Securities Act there occurred or occurs an event or development as a result of which such Testing-the-Waters Communication
included or would include an untrue statement of a material fact or omitted or would omit to state a material fact necessary in order
to make the statements therein, in the light of the circumstances existing at that subsequent time, not misleading, the Company will
promptly notify the Representative and will promptly amend or supplement, at its own expense, such Testing-the-Waters Communication to
eliminate or correct such untrue statement or omission.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 13.5pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l)
The Company also covenants with each Underwriter that, without the prior written consent of the Representative on behalf of the Underwriters,
it will not, and will not publicly disclose an intention to, during the period ending 90 days after the date of the Prospectus (the &ldquo;<B>Restricted
Period</B>&rdquo;), (1) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract
to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, any shares
of Common Stock or any securities convertible into or exercisable or exchangeable for Common Stock, or (2) enter into any swap or other
arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of the Common Stock, whether
any such transaction described in clause 1 or 2 above is to be settled by delivery of Common Stock or such other securities, in cash
or otherwise or (3) file any registration statement with the Commission relating to the offering of any shares of Common Stock or any
securities convertible into or exercisable or exchangeable for Common Stock. The restrictions contained in the preceding paragraph shall
not apply to (A) the Securities to be sold hereunder, (B) the issuance by the Company of shares of Common Stock upon the exercise (including
any net exercise) of an option or warrant or the conversion of a security outstanding on the date hereof and described in the Time of
Sale Prospectus, (C) the issuance by the Company of options, restricted stock units or restricted stock awards (including the Common
Stock issued upon the settlement or exercise thereof) to employees, officers, directors, advisors, or consultants of the Company pursuant
to employee benefit plans (including equity incentive plans) described in the Time of Sale Prospectus and the Prospectus, <I>provided</I>
that, prior to the issuance of any such options, restricted stock units or restricted stock awards, the Company shall cause each recipient
of such securities who is a director or executive officer of the Company to execute and deliver a lock-up agreement substantially in
the form of <U>Exhibit A</U> hereto, (D) the filing by the Company of registration statements on Form S-8 with respect to employee benefit
plans (including any employee benefit plans assumed pursuant to clause (H)), (E) the filing by the Company of a shelf registration
statement on Form S-3 (and amendments thereto) solely to replace the Company&rsquo;s current shelf registration statement on Form S-3
(File No. 333-269100) which was declared effective by the Commission on January 11, 2023, and which becomes stale on January 11, 2026),
including a prospectus relating to certain securities, including common stock, preferred stock, debt securities, warrants and units,
to be issued from time to time by the Company, (F) the filing by the Company of a prospectus supplement pursuant to the Company&rsquo;s
current resale shelf registration statement on Form S-3 (File No. 333-286005) which was declared effective by the Commission on December
1, 2025, (G) the establishment of a trading plan pursuant to Rule 10b5-1 under the Exchange Act for the transfer of shares of Common
Stock, <I>provided</I> that (1) such plan does not provide for the transfer of Common Stock during the <FONT STYLE="letter-spacing: -0.15pt">Restricted</FONT>
Period and (2) to the extent a public announcement or filing under the Exchange Act, if any, is required of or voluntarily made by the
Company regarding the establishment of such plan, such announcement or filing shall include a statement to the effect that no transfer
of Common Stock may be made under such plan during the Restricted Period), and (H) the issuance by the Company of shares of Common Stock
or securities convertible into, exchangeable for or that represent the right to receive Common Stock in connection with (1) the acquisition
by the Company or any of its subsidiaries of the securities, business, technology, property or other assets of another person or entity
or pursuant to an employee benefit plan assumed by the Company in connection with such acquisition, (2) the Company&rsquo;s joint ventures,
equipment leasing arrangements, licensing transactions, collaborations and other strategic transactions; provided that the aggregate
number of shares of Common Stock that the Company may sell or issue or agree to sell or issue pursuant to this clause (H) shall not exceed
5% of the total number of shares of Common Stock outstanding immediately following the completion of the transactions contemplated by
this Agreement and the Company shall cause each recipient of such securities to execute and deliver to the Representative, on or prior
to the issuance of such securities, a lock-up agreement on substantially the same terms as the lock-up letter described in Section 5(h)
hereof to the extent and for the duration that such terms remain in effect at the time of the transfer.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 13.5pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; letter-spacing: -0.15pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 13.5pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; letter-spacing: -0.15pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.
<I>Covenants of the Underwriters</I>. Each Underwriter, severally and not jointly, covenants with the Company not to take any action
that would result in the Company being required to file with the Commission under Rule 433(d) a free writing prospectus prepared by or
on behalf of such Underwriter that otherwise would not be required to be filed by the Company thereunder, but for the action of the Underwriter.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.
<I>Indemnity and Contribution.</I> (a) The Company agrees to indemnify and hold harmless each Underwriter, its affiliates, directors,
officers, employees and agents, and each person, if any, who controls any Underwriter within the meaning of either Section 15 of the
Securities Act or Section 20 of the Exchange Act and each affiliate of any Underwriter within the meaning of Rule 405 under the Securities
Act from and against any and all losses, claims, damages and liabilities (including, without limitation, any legal or other expenses
reasonably incurred in connection with defending or investigating any such action or claim) that arise out of, or are based upon, any
untrue statement or alleged untrue statement of a material fact contained in the Registration Statement or any amendment thereof, any
preliminary prospectus, the Time of Sale Prospectus or any amendment or supplement thereto, any issuer free writing prospectus as defined
in Rule 433(h) under the Securities Act, any Company information that the Company has filed, or is required to file, pursuant to Rule
433(d) under the Securities Act, any &ldquo;road show&rdquo; as defined in Rule 433(h) under the Securities Act (a &ldquo;road show&rdquo;),
the Prospectus or any amendment or supplement thereto, or any Testing-the-Waters Communication, or arise out of, or are based upon, any
omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein
not misleading, except insofar as such losses, claims, damages or liabilities arise out of, or are based upon, any such untrue statement
or omission or alleged untrue statement or omission made in reliance upon and in conformity with any information relating to any Underwriter
furnished to the Company in writing by such Underwriter through the Representative expressly for use therein, it being understood and
agreed that the only such information furnished by the Underwriters through the Representative consists of the Underwriter Information.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Each Underwriter agrees, severally and not jointly, to indemnify and hold harmless the Company, its directors, its officers who sign
the Registration Statement and each person, if any, who controls the Company within the meaning of either Section 15 of the Securities
Act or Section 20 of the Exchange Act to the same extent as the foregoing indemnity from the Company to such Underwriter, but only with
reference to information relating to such Underwriter furnished to the Company in writing by such Underwriter through the Representative
expressly for use in the Registration Statement, any preliminary prospectus, the Time of Sale Prospectus, any issuer free writing prospectus,
road show, or the Prospectus or any amendment or supplement thereto; it being understood and agreed that the only such information furnished
in writing by any such Underwriter through the Representative consists of the following information in the Prospectus under the caption
&ldquo;Underwriters&rdquo; (collectively, the &ldquo;<B>Underwriter Information</B>&rdquo;): (i) the concession and reallowance figures
appearing in the third paragraph (which, for the avoidance of doubt, starts with &ldquo;The underwriters initially propose to offer&hellip;&rdquo;);
and (ii) the information contained in the thirteenth paragraph relating to stabilizing transactions (which, for the avoidance of doubt,
starts with &ldquo;In connection with this offering, the underwriters may engage in stabilizing transactions&hellip;&rdquo;.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 13.5pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 13.5pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
In case any proceeding (including any governmental investigation) shall be instituted involving any person in respect of which indemnity
may be sought pursuant to Section 8(a) or 8(b), such person (the &ldquo;<B>indemnified party</B>&rdquo;) shall promptly notify the person
against whom such indemnity may be sought (the &ldquo;<B>indemnifying party</B>&rdquo;) in writing and the indemnifying party, upon request
of the indemnified party, shall retain counsel reasonably satisfactory to the indemnified party to represent the indemnified party and
any others the indemnifying party may designate in such proceeding and shall pay the reasonably incurred fees and disbursements of such
counsel related to such proceeding. In any such proceeding, any indemnified party shall have the right to retain its own counsel, but
the fees and expenses of such counsel shall be at the expense of such indemnified party unless (i) the indemnifying party and the indemnified
party shall have mutually agreed to the retention of such counsel or (ii) the named parties to any such proceeding (including any impleaded
parties) include both the indemnifying party and the indemnified party and representation of both parties by the same counsel would be
inappropriate due to actual or potential differing interests between them. It is understood that the indemnifying party shall not, in
respect of the legal expenses of any indemnified party in connection with any proceeding or related proceedings in the same jurisdiction,
be liable for the fees and expenses of more than one separate firm (in addition to any local counsel) for all such indemnified parties
and that all such fees and expenses shall be reimbursed as they are incurred. Such firm shall be designated in writing by the Representative,
in the case of parties indemnified pursuant to Section &lrm;8(a), and by the Company, in the case of parties indemnified pursuant to
Section &lrm;8(b). The indemnifying party shall not be liable for any settlement of any proceeding effected without its written consent,
but if settled with such consent or if there be a final judgment for the plaintiff, the indemnifying party agrees to indemnify the indemnified
party from and against any loss or liability by reason of such settlement or judgment. Notwithstanding the foregoing sentence, if at
any time an indemnified party shall have requested an indemnifying party to reimburse the indemnified party for fees and expenses of
counsel as contemplated by the second and third sentences of this paragraph, the indemnifying party agrees that it shall be liable for
any settlement of any proceeding effected without its written consent if (i) such settlement is entered into more than 30 days after
receipt by such indemnifying party of the aforesaid request and (ii) such indemnifying party shall not have reimbursed the indemnified
party in accordance with such request prior to the date of such settlement. No indemnifying party shall, without the prior written consent
of the indemnified party, effect any settlement of any pending or threatened proceeding in respect of which any indemnified party is
or could have been a party and indemnity could have been sought hereunder by such indemnified party, unless such settlement includes
an unconditional release of such indemnified party from all liability on claims that are the subject matter of such proceeding.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 13.5pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 13.5pt; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 13.5pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
To the extent the indemnification provided for in Section 8(a) or 8(b) is unavailable to an indemnified party or insufficient in respect
of any losses, claims, damages or liabilities referred to therein, then each indemnifying party under such paragraph, in lieu of indemnifying
such indemnified party thereunder, shall contribute to the amount paid or payable by such indemnified party as a result of such losses,
claims, damages or liabilities (i) in such proportion as is appropriate to reflect the relative benefits received by the Company on the
one hand and the Underwriters on the other hand from the offering of the Securities or (ii) if the allocation provided by clause 8(d)(i)
above is not permitted by applicable law, in such proportion as is appropriate to reflect not only the relative benefits referred to
in clause 8(d)(i) above but also the relative fault of the Company on the one hand and of the Underwriters on the other hand in connection
with the statements or omissions that resulted in such losses, claims, damages or liabilities, as well as any other relevant equitable
considerations. The relative benefits received by the Company on the one hand and the Underwriters on the other hand in connection with
the offering of the Securities shall be deemed to be in the same respective proportions as the net proceeds from the offering of the
Securities (before deducting expenses) received by the Company and the total underwriting discounts and commissions received by the Underwriters,
in each case as set forth in the table on the cover of the Prospectus, bear to the aggregate Public Offering Price of the Shares and
Public Offering Price per Warrant of the Pre-Funded Warrants. The relative fault of the Company on the one hand and the Underwriters
on the other hand shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material
fact or the omission or alleged omission to state a material fact relates to information supplied by the Company or by the Underwriters
and the parties&rsquo; relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission.
The Underwriters&rsquo; respective obligations to contribute pursuant to this Section 8 are several in proportion to the respective number
of Securities they have purchased hereunder, and not joint.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 13.5pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
The Company and the Underwriters agree that it would not be just or equitable if contribution pursuant to this Section 8 were determined
by <I>pro rata</I> allocation (even if the Underwriters were treated as one entity for such purpose) or by any other method of allocation
that does not take account of the equitable considerations referred to in Section 8(d). The amount paid or payable by an indemnified
party as a result of the losses, claims, damages and liabilities referred to in Section 8(d) shall be deemed to include, subject to the
limitations set forth above, any legal or other expenses reasonably incurred by such indemnified party in connection with investigating
or defending any such action or claim. Notwithstanding the provisions of this Section 8, no Underwriter shall be required to contribute
any amount in excess of the amount by which the total price at which the Securities underwritten by it and distributed to the public
were offered to the public exceeds the amount of any damages that such Underwriter has otherwise been required to pay by reason of such
untrue or alleged untrue statement or omission or alleged omission. No person guilty of fraudulent misrepresentation (within the meaning
of Section 11(f) of the Securities Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation.
The remedies provided for in this Section 8 are not exclusive and shall not limit any rights or remedies which may otherwise be available
to any indemnified party at law or in equity.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 13.5pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 13.5pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
The indemnity and contribution provisions contained in this Section 8 and the representations, warranties and other statements of the
Company contained in this Agreement shall remain operative and in full force and effect regardless of (i) any termination of this Agreement,
(ii) any investigation made by or on behalf of any Underwriter, the directors, officers, employees and agents of the Underwriters, any
person controlling any Underwriter or any affiliate of any Underwriter or by or on behalf of the Company, its officers or directors or
any person controlling the Company and (iii) acceptance of and payment for any of the Securities.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 13.5pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.
<I>Termination</I>. The Underwriters may terminate this Agreement at their discretion by notice given by the Representative to the Company,
if after the execution and delivery of this Agreement and prior to or on the Closing Date (i) trading generally shall have been suspended
or materially limited on, or by, as the case may be, any of the New York Stock Exchange, the NYSE American, the Nasdaq Capital Market,
the Nasdaq Global Select Market, the Chicago Board of Options Exchange, the Chicago Mercantile Exchange or the Chicago Board of Trade,
(ii) trading of any securities of the Company shall have been suspended on any exchange or in any over-the-counter market, (iii) a material
disruption in securities settlement, payment or clearance services in the United States shall have occurred, (iv) any moratorium on commercial
banking activities shall have been declared by Federal or New York State authorities or (v) there shall have occurred any outbreak or
escalation of hostilities, or any change in financial markets or any calamity or crisis that, in the judgment of the Representative,
is material and adverse and which, singly or together with any other event specified in this clause (v), makes it, in the judgment of
the Representative, impracticable or inadvisable to proceed with the offer, sale or delivery of the Securities on the terms and in the
manner contemplated in the Time of Sale Prospectus or the Prospectus.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.
<I>Effectiveness; Defaulting Underwriters</I>. This Agreement shall become effective upon the execution and delivery hereof by the parties
hereto.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If,
on the Closing Date, any one or more of the Underwriters shall fail or refuse to purchase Securities that it has or they have agreed
to purchase hereunder on such date, and the aggregate number of Securities which such defaulting Underwriter or Underwriters agreed but
failed or refused to purchase is not more than one-tenth of the aggregate number of the Securities to be purchased on such date, the
other Underwriters shall be obligated severally in the proportions that the number of Securities set forth opposite their respective
names in <U>Schedule I</U> bears to the aggregate number of Securities set forth opposite the names of all such non-defaulting Underwriters,
or in such other proportions as the Representative may specify, to purchase the Securities which such defaulting Underwriter or Underwriters
agreed but failed or refused to purchase on such date; <I>provided</I> that in no event shall the number of Securities that any Underwriter
has agreed to purchase pursuant to this Agreement be increased pursuant to this Section 10 by an amount in excess of one-ninth of such
number of Securities without the written consent of such Underwriter. If, on the Closing Date, any Underwriter or Underwriters shall
fail or refuse to purchase Securities and the aggregate number of Securities with respect to which such default occurs is more than one-tenth
of the aggregate number of Securities to be purchased on such date, and arrangements satisfactory to the Representative and the Company
for the purchase of such Securities are not made within 36 hours after such default, this Agreement shall terminate without liability
on the part of any non-defaulting Underwriter or the Company. In any such case either the Representative or the Company shall have the
right to postpone the Closing Date, but in no event for longer than seven days, in order that the required changes, if any, in the Registration
Statement, in the Time of Sale Prospectus, in the Prospectus or in any other documents or arrangements may be effected. Any action taken
under this paragraph shall not relieve any defaulting Underwriter from liability in respect of any default of such Underwriter under
this Agreement.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
this Agreement shall be terminated by the Underwriters, or any of them, because of any failure or refusal on the part of the Company
to comply with the terms or to fulfill any of the conditions of this Agreement, or if for any reason the Company shall be unable to perform
its obligations under this Agreement, the Company will reimburse the Underwriters or such Underwriters as have so terminated this Agreement
with respect to themselves, severally, for all out-of-pocket expenses (including the fees and disbursements of their counsel) reasonably
incurred by such Underwriters in connection with this Agreement or the offering contemplated hereunder.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.
<I>Entire Agreement</I>. (a) This Agreement, together with any contemporaneous written agreements and any prior written agreements (to
the extent not superseded by this Agreement) that relate to the offering of the Securities, represents the entire agreement between the
Company and the Underwriters with respect to the preparation of any preliminary prospectus, the Time of Sale Prospectus, the Prospectus,
the conduct of the offering, and the purchase and sale of the Securities.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0.25in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
The Company acknowledges that in connection with the offering of the Securities including with respect to the determination of the public
offering price of the Securities and any related discounts and commissions: (i) the Underwriters have acted at arm&rsquo;s length, are
not agents of, and owe no fiduciary duties to, the Company or any other person, (ii) the Underwriters owe the Company only those duties
and obligations set forth in this Agreement and prior written agreements (to the extent not superseded by this Agreement), if any, (iii)
the Underwriters may have interests that differ from those of the Company, and (iv) none of the activities of the Underwriters in connection
with the transactions contemplated herein constitutes a recommendation, investment advice, or solicitation of any action by the Underwriters
with respect to any entity or natural person. The Company waives to the full extent permitted by applicable law any claims it may have
against the Underwriters arising from an alleged breach of fiduciary duty in connection with the offering of the Securities.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 13.5pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.
<I>Recognition of the U.S. Special Resolution Regimes</I>. (a) In the event that any Underwriter that is a Covered Entity becomes subject
to a proceeding under a U.S. Special Resolution Regime, the transfer from such Underwriter of this Agreement, and any interest and obligation
in or under this Agreement, will be effective to the same extent as the transfer would be effective under the U.S. Special Resolution
Regime if this Agreement, and any such interest and obligation, were governed by the laws of the United States or a state of the United
States.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
In the event that any Underwriter that is a Covered Entity or a BHC Act Affiliate of such Underwriter becomes subject to a proceeding
under a U.S. Special Resolution Regime, Default Rights under this Agreement that may be exercised against such Underwriter are permitted
to be exercised to no greater extent than such Default Rights could be exercised under the U.S. Special Resolution Regime if this Agreement
were governed by the laws of the United States or a state of the United States.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 13.5pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
purposes of this Section a &ldquo;<B>BHC Act Affiliate</B>&rdquo; has the meaning assigned to the term &ldquo;affiliate&rdquo; in, and
shall be interpreted in accordance with, 12 U.S.C. &sect; 1841(k). &ldquo;<B>Covered Entity</B>&rdquo; means any of the following: (i)
a &ldquo;covered entity&rdquo; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &sect; 252.82(b); (ii) a &ldquo;covered
bank&rdquo; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &sect; 47.3(b); or (iii) a &ldquo;covered FSI&rdquo;
as that term is defined in, and interpreted in accordance with, 12 C.F.R. &sect; 382.2(b). &ldquo;<B>Default Right</B>&rdquo; has the
meaning assigned to that term in, and shall be interpreted in accordance with, 12 C.F.R. &sect;&sect; 252.81, 47.2 or 382.1, as applicable.
&ldquo;<B>U.S. Special Resolution Regime</B>&rdquo; means each of (i) the Federal Deposit Insurance Act and the regulations promulgated
thereunder and (ii) Title II of the Dodd-Frank Wall Street Reform and Consumer Protection Act and the regulations promulgated thereunder.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.
<I>Counterparts</I>. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of
which together shall constitute one and the same instrument. Delivery of an executed copy of this Agreement by one party to the other
may be made by facsimile or other electronic transmission (including pdf or any electronic signature complying with the U.S. federal
ESIGN Act of 2000, e.g., www.docusign.com or www.echosign.com) or other transmission method and any counterpart so delivered shall be
deemed to have been duly and validly delivered and be valid and effective for all purposes.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.
<I>Applicable Law</I>. This Agreement shall be governed by and construed in accordance with the internal laws of the State of New York.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.
<I>Headings</I>. The headings of the sections of this Agreement have been inserted for convenience of reference only and shall not be
deemed a part of this Agreement.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16.
<I>Notices. </I>All notices and other communications hereunder shall be in writing and shall be deemed to have been duly given if mailed
or transmitted by any standard form of telecommunication and shall only be effective upon receipt. Notices to the Underwriters shall
be delivered, mailed or sent to Morgan Stanley &amp; Co. LLC, at 1585 Broadway, New York, New York 10036, Attention: Equity Syndicate
Desk, with a copy to the Legal Department. Notices to the Company shall be delivered, mailed or sent to Immix Biopharma, Inc. 11400 West
Olympic Boulevard, Suite 200, Los Angeles, California, 90064, attention: Illya Rachman and Gabriel Morris.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Very
    truly yours,</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>IMMIX
    BIOPHARMA, INC.</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 45%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Ilya Rachman</I></FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> Ilya Rachman </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> Chief Executive Officer </TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[<I>Signature
Page &ndash; Underwriting Agreement</I>]</FONT></P>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 28 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accepted
    as of the date hereof</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Morgan
    Stanley &amp; Co. LLC</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Acting
    severally on behalf of itself and the several Underwriters named in Schedule I hereto.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; white-space: nowrap; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>MORGAN
    STANLEY &amp; CO. LLC</B></FONT></TD>
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Chirag D. Surti</I></FONT> </TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> Chirag D. Surti </TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> Executive Director </TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[<I>Signature
Page &ndash; Underwriting Agreement</I>]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 29 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule
I</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"> Underwriter </TD><TD STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number
                                            of Shares To Be</B></FONT> </P> <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Purchased</B></FONT> </P></TD><TD STYLE="padding-bottom: 1pt"> &nbsp; </TD><TD STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number
                                            of</B></FONT> </P>
                                                           <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Pre-Funded
                                            Warrants To</B></FONT> </P> <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Be
                                            Purchased</B></FONT> </P></TD><TD STYLE="padding-bottom: 1pt"> &nbsp; </TD><TD STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Total</B></FONT> </P></TD><TD STYLE="padding-bottom: 1pt"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%; text-align: left"> Morgan Stanley &amp; Co. LLC </TD><TD STYLE="width: 2%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 12%; text-align: right"> 15,294,118 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 2%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 12%; text-align: right"> 392,158 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 2%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 12%; text-align: right"> 15,686,276 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Citizens JMP Securities, LLC </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 1,911,764 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 49,019 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 1,960,783 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt"> Mizuho Securities USA LLC </TD><TD STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"> 1,911,764 </TD><TD STYLE="padding-bottom: 1pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"> 49,019 </TD><TD STYLE="padding-bottom: 1pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"> 1,960,783 </TD><TD STYLE="padding-bottom: 1pt; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"> Total: </TD><TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> 19,117,646 </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> 490,196 </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> 19,607,842 </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"> &nbsp; </TD></TR>
  </TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>&nbsp;</P>


<!-- Field: Page; Sequence: 30; Options: NewSection -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">I-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule
II</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Time
of Sale Prospectus</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
<TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>a.</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Pricing
                                            Disclosure Package</B></FONT></TD>
</TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Free
writing prospectus dated December 7, 2025</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
<TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>b.</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Pricing
                                            Information Provided Orally by Underwriters</B></FONT></TD>
</TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Public
Offering Price per Share: $5.10</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number
of Shares: 19,117,646</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Public
Offering Price per Pre-Funded Warrant: $5.09</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number
of Pre-Funded Warrants: 490,196</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 31; Options: NewSection -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EXHIBIT
A</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FORM
OF LOCK-UP AGREEMENT</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>[Attached]</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<!-- Field: Page; Sequence: 32; Options: NewSection -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Final
Form</I></B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FORM
OF LOCK-UP AGREEMENT</B></FONT> </P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">November
30, 2025</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Morgan
Stanley &amp; Co. LLC</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c/o
Morgan Stanley &amp; Co. LLC</FONT> </P>

<P STYLE="margin-left: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1585
Broadway</FONT> </P>

<P STYLE="margin-left: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="margin-left: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
York, New York 10036</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ladies
and Gentlemen:</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
undersigned understands that Morgan Stanley &amp; Co. LLC (&ldquo;<B>Morgan Stanley</B>&rdquo;) proposes to enter into an Underwriting
Agreement (the &ldquo;<B>Underwriting Agreement</B>&rdquo;) with Immix Biopharma, Inc. (&ldquo;<B>Immix</B>&rdquo; or the &ldquo;<B>Company</B>&rdquo;),
a Delaware corporation (the &ldquo;<B>Company</B>&rdquo;) providing for the public offering (the &ldquo;<B>Public Offering</B>&rdquo;)
by the several underwriters listed on Schedule I to the Underwriting Agreement, including Morgan Stanley (the &ldquo;<B>Underwriters</B>&rdquo;),
of shares (the &ldquo;<B>Shares</B>&rdquo;) of the common stock, par value $0.0001 per share, of the Company (the &ldquo;<B>Common Stock</B>&rdquo;).
To the extent that there are no additional Underwriters listed on Schedule I to the Underwriting Agreement other than Morgan Stanley,
the term Underwriters shall mean the singular as the context requires.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
induce the Underwriters that may participate in the Public Offering to continue their efforts in connection with the Public Offering,
the undersigned hereby agrees that, without the prior written consent of Morgan Stanley on behalf of the Underwriters, it will not, and
will not publicly disclose an intention to, during the period commencing on the date hereof and ending 90 days after the date of the
final prospectus supplement (the &ldquo;<B>Restricted Period</B>&rdquo;) relating to the Public Offering (the &ldquo;<B>Prospectus</B>&rdquo;),
(1) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any
option, right or warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock beneficially
owned (as such term is used in Rule 13d-3 of the Securities Exchange Act of 1934, as amended (the &ldquo;<B>Exchange Act</B>&rdquo;)),
by the undersigned or any other securities so owned convertible into or exercisable or exchangeable for Common Stock (such options, rights
warrants or other securities, collectively, &ldquo;<B>Derivative Instruments</B>&rdquo;) or (2) enter into any swap or other arrangement
that transfers to another, in whole or in part, any of the economic consequences of ownership of the Common Stock, whether any such transaction
described in clause (1) or (2) above is to be settled by delivery of Common Stock or such other securities, in cash or otherwise. Except
as set forth under clauses (e), (f), (h) and (i) below, the undersigned represents and warrants that the undersigned is not, and has
not caused or directed any of its affiliates to be or become, currently a party to any agreement or arrangement that provides for, is
designed to or which reasonably could be expected to lead to or result in any transfer of Common Stock or Derivative Instruments beneficially
owned by the undersigned. The first sentence of this paragraph shall not apply to:</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>




<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT> </TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">transfers
                                            of shares of Common Stock or any security convertible into or exercisable or exchangeable
                                            for Common Stock (i) as a bona fide gift or charitable contribution, (ii) to an immediate
                                            family member of the undersigned or a trust for the direct or indirect benefit of the undersigned
                                            or one or more immediate family member of the undersigned (for purposes of this letter agreement,
                                            &ldquo;<B>immediate family member</B>&rdquo; shall mean any relationship by blood, marriage
                                            or adoption, not more remote than first cousin), (iii) if the undersigned is a trust, to
                                            a trustor or beneficiary of the trust or to the estate of a beneficiary of such trust, (iv)
                                            if the undersigned is a corporation, partnership, limited liability company, trust or other
                                            business entity, to another corporation, partnership, limited liability company, trust or
                                            other business entity that is an affiliate (as defined in Rule 405 promulgated under the
                                            Securities Act of 1933, as amended) of the undersigned, or to any investment fund or other
                                            entity controlled or managed by the undersigned or affiliates of the undersigned, or as part
                                            of a distribution, transfer or disposition without consideration by the undersigned to its
                                            stockholders, current or former partners (general or limited), members, beneficiaries or
                                            other equity holders, or to the estates of any such stockholders, partners, members, beneficiaries
                                            or other equity holders, (v) by will, other testamentary document or intestate succession
                                            to the legal representative, heir, beneficiary or a member of the immediate family of the
                                            undersigned, or (vi) to a nominee or custodian of a person or entity to whom a disposition
                                            or transfer would be permissible under clauses (a)(i) through (a)(v); <I>provided </I>that
                                            (x) in the case of any transfer or distribution pursuant to this clause (a), each transferee
                                            shall sign and deliver a lock-up letter substantially in the form of this letter agreement
                                            and such transfer shall not involve a disposition of value, (y) in the case of any transfer
                                            or distribution pursuant to clause (a)(iv), no filing by any party (donor, done, devisee,
                                            transferor, transferee, distributer or distribute) under Section 16(a) of the Exchange Act,
                                            or other public announcement shall be required or shall be made voluntarily in connection
                                            with such transfer or distribution (other than a filing on a Form 5 made after the expiration
                                            of the Restricted Period), and (z) in the case of any transfer or distribution pursuant to
                                            clause (a)(i), (ii), (iii), (v) and (vi), it shall be a condition to such transfer that no
                                            public filing, report or announcement shall be voluntarily made, and if any filing under
                                            Section 16(a) of the Exchange Act, or other public filing, report or announcement reporting
                                            a reduction in beneficial ownership of shares of Common Stock in connection with such transfer
                                            or distribution shall be legally required during the Restricted Period, such filing, report
                                            or announcement shall clearly indicate in the footnotes thereto the nature and conditions
                                            of such transfer;</FONT> </TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT> </TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">transfers
                                            of shares of Common Stock or any securities convertible into or exercisable or exchangeable
                                            for Common Stock that occur by operation of law pursuant to a qualified domestic order or
                                            in connection with a divorce settlement, <I>provided </I>that no public filing, report or
                                            announcement shall be voluntarily made, and any filing required to be made under Section
                                            16(a) of the Exchange Act shall clearly indicate in the footnotes thereto that such transfer
                                            is pursuant to a qualified domestic order or in connection with a divorce settlement;</FONT> </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT> </TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">transfers
                                            of shares of Common Stock or any securities convertible into or exercisable or exchangeable
                                            for Common Stock to the Company pursuant to agreements under which the Company has the option
                                            to repurchase such shares or securities upon termination of service of the undersigned or
                                            a right of first refusal with respect to transfers of such shares, <I>provided </I>that such
                                            agreements are described in the Company&rsquo;s filings with the Securities and Exchange
                                            Commission (the &ldquo;<B>SEC</B>&rdquo;) and <I>provided, further </I>that no public filing,
                                            report or announcement shall be voluntarily made, and any filing required to be made under
                                            Section 16(a) of the Exchange Act shall clearly indicate in the footnotes thereto that such
                                            transfer is pursuant to the circumstances described in this clause (c);</FONT> </TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT> </TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            exercise of any stock option by or the vesting and settlement of any restricted stock unit
                                            of the undersigned outstanding as of the date hereof or that was granted under a stock incentive
                                            plan or stock purchase plan described in the Company&rsquo;s filings with the SEC, <I>provided</I>
                                            that the shares received upon exercise or vesting or settlement shall continue to be subject
                                            to this letter agreement and <I>provided, further </I>that any filing required to be made
                                            under Section 16(a) of the Exchange Act shall clearly indicate in the footnotes thereto that
                                            the filing relates to the exercise of a stock option or settlement of a restricted stock
                                            unit, that no shares were sold by the reporting person and that the shares received upon
                                            exercise of the stock option or settlement of the restricted stock unit are subject to the
                                            terms of this letter agreement;</FONT> </TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT> </TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">transfers
                                            of shares of Common Stock to the Company upon the exercise of stock options outstanding as
                                            of the date hereof or that were granted pursuant to a stock incentive plan or stock purchase
                                            plan described in the Company&rsquo;s filings with the SEC, on a &ldquo;cashless&rdquo; or
                                            &ldquo;net exercise&rdquo; basis, <I>provided</I> that the shares received upon exercise
                                            shall continue to be subject to this letter agreement and <I>provided, further</I> that no
                                            public filing, report or announcement shall be voluntarily made, and any filing required
                                            to be made under Section 16(a) of the Exchange Act shall clearly indicate in the footnotes
                                            thereto that the filing relates to the &ldquo;cashless&rdquo; or &ldquo;net&rdquo; exercise
                                            of a stock option, that no shares were sold by the reporting person and that the shares received
                                            upon exercise of the stock option are subject to the terms of this letter agreement;</FONT> </TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT> </TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">transfers
                                            of shares of Common Stock to the Company, or the withholding of shares of Common Stock by
                                            the Company, in connection with a vesting event or subsequent settlement (as applicable)
                                            of restricted stock awards or restricted stock units, in each case which are outstanding
                                            as of the date hereof or were granted pursuant to a stock incentive plan or stock purchase
                                            plan described in the Company&rsquo;s filings with the SEC, to cover tax withholding obligations
                                            or the payment of taxes, including estimated taxes, due in connection with the vesting event,
                                            <I>provided </I>that no public filing, report or announcement shall be voluntarily made,
                                            and any filing required to be made under Section 16(a) of the Exchange Act shall clearly
                                            indicate in the footnotes thereto that the purpose of such transfer is to cover such tax
                                            withholding obligations or the payment of taxes due in connection with the vesting event;</FONT> </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)</FONT> </TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">transfers
                                            of shares pursuant to a bona fide third-party tender offer, merger, consolidation, other
                                            similar transaction or series of related transactions involving a Change of Control (as defined
                                            below) of the Company (including, without limitation, entering into any lock-up, voting or
                                            similar agreement pursuant to which the undersigned may agree to transfer, sell, tender or
                                            otherwise dispose of Common Stock or other securities in connection with any such transaction,
                                            or vote any securities in favor of any such transaction), provided that in the event that
                                            such Change of Control is not completed, the undersigned&rsquo;s shares shall remain subject
                                            to this letter agreement and title to the undersigned&rsquo;s shares shall remain with the
                                            undersigned;</FONT> </TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)</FONT> </TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">transfers
                                            of shares pursuant to a trading plan established pursuant to Rule 10b5-1 under the Exchange
                                            Act (a &ldquo;<B>10b5-1 Plan</B>&rdquo;) that has been disclosed to the Underwriters and
                                            entered into by the undersigned prior to the date of this letter agreement, <I>provided </I>that
                                            no public filing, report or announcement shall be voluntarily made, and any filing required
                                            to be made under Section 16(a) of the Exchange Act shall clearly indicate in the footnotes
                                            thereto that such transfer is pursuant to a 10b5-1 Plan; or</FONT> </TD></TR><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD></TR>
                                                                                                                        <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> (i) </TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"> the
                                            establishment or amendment of a 10b5-1 Plan for the transfer of shares of Common Stock, provided
                                            that (i) such plan does not provide for the transfer of Common Stock during the Restricted
                                            Period and (ii) to the extent a public announcement or filing under the Exchange Act, if
                                            any, is required of or voluntarily made by or on behalf of the undersigned or the Company
                                            regarding the establishment of such plan, such announcement or filing shall include a statement
                                            to the effect that no transfer of Common Stock may be made under such plan during the Restricted
                                            Period. </TD></TR>
                                                                                                                        </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the undersigned agrees that, without the prior written consent of Morgan Stanley on behalf of the Underwriters, it will not,
during the Restricted Period, make any demand for or exercise any right with respect to, the registration of any shares of Common Stock
or any security convertible into or exercisable or exchangeable for Common Stock.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
undersigned also agrees and consents to the entry of stop transfer instructions with the Company&rsquo;s transfer agent and registrar
against the transfer of the undersigned&rsquo;s shares of Common Stock except in compliance with the foregoing restrictions. &ldquo;<B>Change
of Control</B>&rdquo; means the transfer (whether by tender offer, merger, consolidation, other similar transaction or series of related
transactions), in one transaction or a series of related transactions approved by the Company&rsquo;s board of directors, to a person
or group of affiliated persons, of the Company&rsquo;s voting securities if, after such transfer, such person or group of affiliated
persons would hold more than 50% of the outstanding voting securities of the Company (or the surviving entity) <I>provided </I>that,
for the avoidance of doubt, the Public Offering shall not constitute a Change of Control.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the undersigned is not a natural person, the undersigned represents and warrants that no single natural person, entity or &ldquo;group&rdquo;
(within the meaning of Section 13(d)(3) of the Exchange Act), other than a natural person, entity or &ldquo;group&rdquo; (as described
above) that has executed a lock-up agreement in substantially the same form as this letter agreement, beneficially owns, directly or
indirectly, 50% or more of the common equity interests, or 50% or more of the voting power, in the undersigned.</FONT> </P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
undersigned understands that the Company and the Underwriters are relying upon this letter agreement in proceeding towards the consummation
of the Public Offering. The undersigned further understands that this letter agreement is irrevocable and shall be binding upon the undersigned&rsquo;s
heirs, legal representatives, successors and assigns.</FONT> </P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
undersigned acknowledges and agrees that the Underwriters have not provided any recommendation or investment advice nor have the Underwriters
solicited any action from the undersigned with respect to the Public Offering and the undersigned has consulted their own legal, accounting,
financial, regulatory and tax advisors to the extent deemed appropriate. The undersigned further acknowledges and agrees that, although
the Underwriters may provide certain Regulation Best Interest and Form CRS disclosures or other related documentation to you in connection
with the Public Offering, the Underwriters are not making a recommendation to you to participate in the Public Offering or sell any Shares
at the price determined in the Public Offering, and nothing set forth in such disclosures or documentation is intended to suggest that
any Underwriter is making such a recommendation.</FONT> </P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
letter agreement shall automatically terminate and the undersigned shall be released from all obligations under this letter agreement
upon the earliest to occur, if any, of (i) the date the Company, on the one hand, or the Underwriters, on the other hand, informs the
other in writing, prior to the execution of the Underwriting Agreement, that it has determined not to proceed with the Public Offering,
(ii) the date the Underwriting Agreement is terminated (other than the provisions thereof which survive termination) prior to payment
for and delivery of the securities to be sold thereunder, and (iii) December 31, 2025, if the Underwriting Agreement has not been executed
by such date (which date may be extended for an additional three months by the Company upon written notice to the undersigned).</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Whether
or not the Public Offering actually occurs depends on a number of factors, including market conditions. Any Public Offering will only
be made pursuant to an Underwriting Agreement, the terms of which are subject to negotiation between the Company and the Underwriters.</FONT> </P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>




<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
letter agreement and any claim, controversy or dispute arising under or related to this agreement shall be governed by and construed
in accordance with the laws of the State of New York, without regard to the conflict of laws principles thereof.</FONT> </P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Electronic
signatures complying with the New York Electronic Signatures and Records Act (N.Y. State Tech. &sect;&sect; 301-309), as amended from
time to time, or other applicable law will be deemed original signatures for purposes of this letter agreement. Transmission by telecopy,
electronic mail or other transmission method of an executed counterpart of this letter agreement will constitute due and sufficient delivery
of such counterpart.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>[Signature
Page Follows]</I></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT> </P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT> </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 50%"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Very
    truly yours,</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Name)</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address)</FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="text-align: center; font: 12pt Times New Roman, Times, Serif; margin-top: 0.5pt; margin-bottom: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Signature
Page &ndash; Lockup <FONT STYLE="letter-spacing: -0.1pt">Agreement</FONT></I></FONT> </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<!-- Field: Page; Sequence: 5; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"> <I>&nbsp;</I> </P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>3
<FILENAME>ex4-1.htm
<DESCRIPTION>EX-4.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="text-indent: 0pt; text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><B>Exhibit 4.1</B></P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FORM
OF PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK</B></FONT></P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number
of Shares: [&nbsp;&nbsp;]</FONT></P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(subject
to adjustment)</FONT></P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrant
    No.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Original
    Issue Date: [&nbsp;&nbsp;], 2025</FONT></TD></TR>
  </TABLE>
<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0pt; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Immix
Biopharma, Inc., a Delaware corporation (the &ldquo;<I>Company</I>&rdquo;), hereby certifies that, for good and valuable consideration,
the receipt and sufficiency of which are hereby acknowledged, [&nbsp;&nbsp;] or its registered assigns (the &ldquo;<I>Holder</I>&rdquo;), is entitled,
subject to the terms set forth below, to purchase from the Company up to a total of [&nbsp;&#8239;] shares of common stock, $0.0001 par value per
share (the &ldquo;<I>Common Stock</I>&rdquo;), of the Company (each such share, a &ldquo;<I>Warrant Share</I>&rdquo; and all such shares,
the &ldquo;<I>Warrant Shares</I>&rdquo;) at an exercise price per share equal to $0.01 per share (as adjusted from time to time as provided
in <U>Section 9</U> herein, the &ldquo;<I>Exercise Price</I>&rdquo;), upon surrender of this <I>Warrant to Purchase Common Stock</I>
(including any <I>Warrants to Purchase Common Stock</I> issued in exchange, transfer or replacement hereof, the &ldquo;<I>Warrant</I>&rdquo;)
at any time and from time to time on or after the date hereof (the &ldquo;<I>Original Issue Date</I>&rdquo;), subject to the following
terms and conditions:</FONT></P>

<P STYLE="text-indent: 0pt; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0pt; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
<U>Definitions</U>. For purposes of this Warrant, the following terms shall have the following meanings:</FONT></P>

<P STYLE="text-indent: 0pt; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
&ldquo;Affiliate&rdquo; means any Person directly or indirectly controlled by, controlling or under common control with, a Holder, but
only for so long as such control shall continue. For purposes of this definition, &ldquo;control&rdquo; (including, with correlative
meanings, &ldquo;controlled by&rdquo;, &ldquo;controlling&rdquo; and &ldquo;under common control with&rdquo;) means, with respect to
a Person, possession, direct or indirect, of (a) the power to direct or cause direction of the management and policies of such Person
(whether through ownership of securities or partnership or other ownership interests, by contract or otherwise), or (b) at least 50%
of the voting securities (whether directly or pursuant to any option, warrant or other similar arrangement) or other comparable equity
interests.</FONT></P>

<P STYLE="text-indent: 0pt; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0pt; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
&ldquo;<I>Commission</I>&rdquo; means the United States Securities and Exchange Commission.</FONT></P>

<P STYLE="text-indent: 0pt; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0pt; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
&ldquo;<I>Closing Sale Price</I>&rdquo; means, for any security as of any date, the last trade price for such security on the Principal
Trading Market for such security, as reported by Bloomberg Financial Markets, or, if such Principal Trading Market begins to operate
on an extended hours basis and does not designate the last trade price, then the last trade price of such security prior to 4:00 P.M.,
New York City time, as reported by Bloomberg Financial Markets, or if the foregoing do not apply, the last trade price of such security
in the over-the-counter market on the electronic bulletin board for such security as reported by Bloomberg Financial Markets, or, if
no last trade price is reported for such security by Bloomberg Financial Markets, the average of the bid and ask prices, of any market
makers for such security as reported in the &ldquo;pink sheets&rdquo; by Pink Sheets LLC. If the Closing Sale Price cannot be calculated
for a security on a particular date on any of the foregoing bases, the Closing Sale Price of such security on such date shall be the
fair market value as mutually determined in good faith by the Company and the Holder. If the Company and the Holder are unable to agree
upon the fair market value of such security, then the Board of Directors of the Company shall use its good faith judgment to determine
the fair market value. The Board of Directors&rsquo; determination shall be binding upon all parties absent demonstrable error. All such
determinations shall be appropriately adjusted for any stock dividend, stock split, stock combination or other similar transaction during
the applicable calculation period.</FONT></P>

<P STYLE="text-indent: 0pt; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0pt; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
&ldquo;<I>Exchange Act</I>&rdquo; means the Securities Exchange Act of 1934, as amended.</FONT></P>

<P STYLE="text-indent: 0pt; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0pt; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
&ldquo;<I>Principal Trading Market</I>&rdquo; means the national securities exchange or other trading market on which the Common Stock
is primarily listed on and quoted for trading, which, as of the Original Issue Date, shall be the Nasdaq Global Select Market.</FONT></P>

<P STYLE="text-indent: 0pt; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0pt; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
&ldquo;<I>Registration Statement</I>&rdquo; means the Company&rsquo;s Registration Statement on Form S-3 (File No. 333-269100), filed
with the Securities and Exchange Commission on January 3, 2023.</FONT></P>

<P STYLE="text-indent: 0pt; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0pt; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)
&ldquo;<I>Securities Act</I>&rdquo; means the Securities Act of 1933, as amended.</FONT></P>

<P STYLE="text-indent: 0pt; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0pt; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)
&ldquo;<I>Trading Day</I>&rdquo; means any weekday on which the Principal Trading Market is normally open for trading.</FONT></P>

<P STYLE="text-indent: 0pt; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0pt; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
&ldquo;<I>Transfer Agent</I>&rdquo; means Pacific Stock Transfer, the Company&rsquo;s transfer agent and registrar for the Common Stock,
and any successor appointed in such capacity.</FONT></P>

<P STYLE="text-indent: 0pt; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0pt; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
<U>Issuance of Securities; Registration of Warrants</U>. The Warrant, as initially issued by the Company, is offered and sold pursuant
to the Registration Statement. As of the Original Issue Date, the Warrant Shares are issuable under the Registration Statement. Accordingly,
the Warrant and, assuming issuance pursuant to the Registration Statement or an exchange meeting the requirements of Section 3(a)(9)
of the Securities Act as in effect on the Original Issue Date, the Warrant Shares, are not &ldquo;restricted securities&rdquo; under
Rule 144 promulgated under the Securities Act. The Company shall register ownership of this Warrant, upon records to be maintained by
the Company for that purpose (the &ldquo;<I>Warrant Register</I>&rdquo;), in the name of the record Holder (which shall include the initial
Holder or, as the case may be, any assignee to which this Warrant is permissibly assigned hereunder) from time to time. The Company may
deem and treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution
to the Holder, and for all other purposes, absent actual notice to the contrary.</FONT></P>

<P STYLE="text-indent: 0pt; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0pt; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
<U>Registration of Transfers</U>. Subject to compliance with all applicable securities laws and the rules of the Principal Trading Market,
the Company shall, or will cause its Transfer Agent to, register the transfer of all or any portion of this Warrant in the Warrant Register,
upon surrender of this Warrant, and payment for all applicable transfer taxes (if any). Upon any such registration or transfer, a new
warrant to purchase Common Stock in substantially the form of this Warrant (any such new warrant, a &ldquo;<I>New Warrant</I>&rdquo;)
evidencing the portion of this Warrant so transferred shall be issued to the transferee, and a New Warrant evidencing the remaining portion
of this Warrant not so transferred, if any, shall be issued to the transferring Holder. The acceptance of the New Warrant by the transferee
thereof shall be deemed the acceptance by such transferee of all of the rights and obligations in respect of the New Warrant that the
Holder has in respect of this Warrant. The Company shall, or will cause its Transfer Agent to, prepare, issue and deliver at the Company&rsquo;s
own expense any New Warrant under this <U>Section 3</U>. Until due presentment for registration of transfer, the Company may treat the
registered Holder hereof as the owner and holder for all purposes, and the Company shall not be affected by any notice to the contrary.</FONT></P>

<P STYLE="text-indent: 0pt; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0pt; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.
<U>Exercise and Duration of Warrants</U>.</FONT></P>

<P STYLE="text-indent: 0pt; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0pt; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
All or any part of this Warrant shall be exercisable by the registered Holder in any manner permitted by this Warrant at any time and
from time to time on or after the Original Issue Date.</FONT></P>

<P STYLE="text-indent: 0pt; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0pt; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
The Holder may exercise this Warrant by delivering to the Company (i) an exercise notice, in the form attached as <U>Schedule 1</U> hereto
(the &ldquo;<I>Exercise Notice</I>&rdquo;), completed and duly signed, and (ii) payment of the Exercise Price for the number of Warrant
Shares as to which this Warrant is being exercised (which may take the form of a &ldquo;cashless exercise&rdquo; if so indicated in the
Exercise Notice pursuant to <U>Section 10</U> below), and the date on which the last of such items is delivered to the Company (as determined
in accordance with the notice provisions hereof) is an &ldquo;<I>Exercise Date</I>.&rdquo; The Holder shall not be required to deliver
the original Warrant in order to effect an exercise hereunder. Execution and delivery of the Exercise Notice shall have the same effect
as cancellation of the original Warrant and issuance of a New Warrant evidencing the right to purchase the remaining number of Warrant
Shares, if any. The aggregate exercise price of this Warrant, except for the Exercise Price, was pre-funded to the Company on or before
the Original Issue Date, and consequently no additional consideration (other than the Exercise Price) shall be required by to be paid
by the Holder to effect any exercise of this Warrant. The Holder shall not be entitled to the return or refund of all, or any portion,
of such pre-funded exercise price under any circumstance or for any reason whatsoever.</FONT></P>

<P STYLE="text-indent: 0pt; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0pt; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.
<U>Delivery of Warrant Shares</U>.</FONT></P>

<P STYLE="text-indent: 0pt; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0pt; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
Upon exercise of this Warrant, the Company shall promptly (but in no event later than five (5) Trading Days after the Exercise Date),
upon the request of the Holder, credit (or cause the Transfer Agent to credit) such aggregate number of shares of Common Stock to which
the Holder is entitled pursuant to such exercise to the Holder&rsquo;s or its designee&rsquo;s balance account with The Depository Trust
Company (&ldquo;<I>DTC</I>&rdquo;) through its Deposit Withdrawal Agent Commission system, or if the Transfer Agent is not participating
in the Fast Automated Securities Transfer Program (the &ldquo;<I>FAST Program</I>&rdquo;) or if the certificates are required to bear
a legend regarding restriction on transferability, issue and dispatch by overnight courier to the address as specified in the Exercise
Notice, a certificate, registered in the Company&rsquo;s share register in the name of the Holder or its designee, for the number of
shares of Common Stock to which the Holder is entitled pursuant to such exercise. The Holder, DTC (or its nominee) or any natural person
or legal entity (each, a &ldquo;Person&rdquo;) so designated by the Holder to receive Warrant Shares, shall be deemed to have become
the holder of record of such Warrant Shares as of the Exercise Date, irrespective of the date such Warrant Shares are credited to the
Holder&rsquo;s DTC account or the date of delivery of the certificates evidencing such Warrant Shares, as the case may be.</FONT></P>

<P STYLE="text-indent: 0pt; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0pt; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
If by the close of the fifth (5th) Trading Day after the Exercise Date, the Company fails to deliver to the Holder a certificate representing
the required number of Warrant Shares in the manner required pursuant to <U>Section 5(a)</U> or fails to credit the Holder&rsquo;s balance
account with DTC for such number of Warrant Shares to which the Holder is entitled, and if after such fifth (5th) Trading Day and prior
to the receipt of such Warrant Shares, the Holder purchases (in an open market transaction or otherwise) shares of Common Stock to deliver
in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise (a &ldquo;<I>Buy-In</I>&rdquo;),
then the Company shall, within five (5) Trading Days after the Holder&rsquo;s request and in the Holder&rsquo;s sole discretion, either
(1) pay in cash to the Holder an amount equal to the Holder&rsquo;s total purchase price (including brokerage commissions, if any) for
the shares of Common Stock so purchased, at which point the Company&rsquo;s obligation to deliver such certificate (and to issue such
Warrant Shares) shall terminate or (2) promptly honor its obligation to deliver to the Holder a certificate or certificates representing
such Warrant Shares or credit the Holder&rsquo;s or its designee&rsquo;s balance account with DTC for such Warrant Shares and pay cash
to the Holder in an amount equal to the excess (if any) of Holder&rsquo;s total purchase price (including brokerage commissions, if any)
for the shares of Common Stock so purchased in the Buy-In over the product of (A) the number of shares of Common Stock purchased in the
Buy-In, times (B) the Closing Sale Price of a share of Common Stock on the Exercise Date.</FONT></P>

<P STYLE="text-indent: 0pt; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0pt; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
To the extent permitted by law and subject to Section 5(b), the Company&rsquo;s obligations to issue and deliver (or to cause the Transfer
Agent to issue and deliver) Warrant Shares in accordance with and subject to the terms hereof (including the limitations set forth in
<U>Section 11</U> below) are absolute and unconditional, irrespective of any action or inaction by the Holder to enforce the same, any
waiver or consent with respect to any provision hereof, the recovery of any judgment against any Person or any action to enforce the
same, or any setoff, counterclaim, recoupment, limitation or termination, or any breach or alleged breach by the Holder or any other
Person of any obligation to the Company or any violation or alleged violation of law by the Holder or any other Person, and irrespective
of any other circumstance that might otherwise limit such obligation of the Company to the Holder in connection with the issuance of
Warrant Shares. Subject to Section 5(b), nothing herein shall limit the Holder&rsquo;s right to pursue any other remedies available to
it hereunder, at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief with respect
to the Company&rsquo;s failure to timely deliver certificates representing shares of Common Stock upon exercise of the Warrant as required
pursuant to the terms hereof.</FONT></P>

<P STYLE="text-indent: 0pt; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0pt; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.
<U>Charges, Taxes and Expenses</U>. Issuance and delivery of certificates for shares of Common Stock upon exercise of this Warrant shall
be made without charge to the Holder for any issue or transfer tax, transfer agent fee or other incidental tax or expense (excluding
any applicable stamp duties) in respect of the issuance of such certificates, all of which taxes and expenses shall be paid by the Company;
<I>provided, however</I>, that the Company shall not be required to pay any tax that may be payable in respect of any transfer involved
in the registration of any certificates for Warrant Shares or the Warrants in a name other than that of the Holder or an Affiliate thereof.
The Holder shall be responsible for all other tax liability that may arise as a result of holding or transferring this Warrant or receiving
Warrant Shares upon exercise hereof.</FONT></P>

<P STYLE="text-indent: 0pt; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0pt; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.
<U>Replacement of Warrant</U>. If this Warrant is mutilated, lost, stolen or destroyed, the Company shall issue or cause to be issued
in exchange and substitution for and upon cancellation hereof, or in lieu of and substitution for this Warrant, a New Warrant, but only
upon receipt of evidence reasonably satisfactory to the Company of such loss, theft or destruction (in such case) and, in each case,
a customary and reasonable indemnity and surety bond, if requested by the Company. Applicants for a New Warrant under such circumstances
shall also comply with such other reasonable regulations and procedures and pay such other reasonable third-party costs as the Company
may prescribe. If a New Warrant is requested as a result of a mutilation of this Warrant, then the Holder shall deliver such mutilated
Warrant to the Company as a condition precedent to the Company&rsquo;s obligation to issue the New Warrant.</FONT></P>

<P STYLE="text-indent: 0pt; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0pt; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.
<U>Reservation of Warrant Shares</U>. The Company covenants that it will, at all times while this Warrant is outstanding, reserve and
keep available out of the aggregate of its authorized but unissued and otherwise unreserved Common Stock, solely for the purpose of enabling
it to issue Warrant Shares upon exercise of this Warrant as herein provided, the number of Warrant Shares that are initially issuable
and deliverable upon the exercise of this entire Warrant, free from preemptive rights or any other contingent purchase rights of persons
other than the Holder (taking into account the adjustments and restrictions of <U>Section 9</U>). The Company covenants that all Warrant
Shares so issuable and deliverable shall, upon issuance and the payment of the applicable Exercise Price in accordance with the terms
hereof, be duly and validly authorized, issued and fully paid and non-assessable. The Company will take all commercially reasonable actions
as may be necessary to assure that such shares of Common Stock may be issued as provided herein without violation of any applicable law
or regulation, or of any requirements of any securities exchange or automated quotation system upon which the Common Stock may be listed.
The Company further covenants that it will not, without the prior written consent of the Holder, take any actions to increase the par
value of the Common Stock at any time while this Warrant is outstanding.</FONT></P>

<P STYLE="text-indent: 0pt; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0pt; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.
<U>Certain Adjustments</U>. The Exercise Price and number of Warrant Shares issuable upon exercise of this Warrant are subject to adjustment
from time to time as set forth in this <U>Section 9</U>.</FONT></P>

<P STYLE="text-indent: 0pt; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0pt; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<U>Stock Dividends and Splits</U>. If the Company, at any time while this Warrant is outstanding, (i) pays a stock dividend on its Common
Stock or otherwise makes a distribution on any class of capital stock issued and outstanding on the Original Issue Date and in accordance
with the terms of such stock on the Original Issue Date or as amended, as described in the Registration Statement, that is payable in
shares of Common Stock, (ii) subdivides its outstanding shares of Common Stock into a larger number of shares of Common Stock, (iii)
combines its outstanding shares of Common Stock into a smaller number of shares of Common Stock or (iv) issues by reclassification of
shares of capital stock any additional shares of Common Stock of the Company, then in each such case the Exercise Price shall be multiplied
by a fraction, the numerator of which shall be the number of shares of Common Stock outstanding immediately before such event and the
denominator of which shall be the number of shares of Common Stock outstanding immediately after such event. Any adjustment made pursuant
to clause (i) of this paragraph shall become effective immediately after the record date for the determination of stockholders entitled
to receive such dividend or distribution, <I>provided, however</I>, that if such record date shall have been fixed and such dividend
is not fully paid on the date fixed therefor, the Exercise Price shall be recomputed accordingly as of the close of business on such
record date and thereafter the Exercise Price shall be adjusted pursuant to this paragraph as of the time of actual payment of such dividends.
Any adjustment pursuant to clause (ii) or (iii) of this paragraph shall become effective immediately after the effective date of such
subdivision or combination.</FONT></P>

<P STYLE="text-indent: 0pt; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0pt; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
<U>Pro Rata Distributions</U>. If the Company, at any time while this Warrant is outstanding, distributes to all holders of Common Stock
for no consideration (i) evidences of its indebtedness, (ii) any security (other than a distribution of Common Stock covered by the preceding
paragraph), (iii) rights or warrants to subscribe for or purchase any security, or (iv) cash or any other asset (in each case, &ldquo;<I>Distributed
Property</I>&rdquo;), then, upon any exercise of this Warrant that occurs after the record date fixed for determination of stockholders
entitled to receive such distribution, the Holder shall be entitled to receive, in addition to the Warrant Shares otherwise issuable
upon such exercise (if applicable), the Distributed Property that such Holder would have been entitled to receive in respect of such
number of Warrant Shares had the Holder been the record holder of such Warrant Shares immediately prior to such record date without regard
to any limitation on exercise contained therein.</FONT></P>

<P STYLE="text-indent: 0pt; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0pt; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
<U>Fundamental Transactions</U>. If, at any time while this Warrant is outstanding (i) the Company effects any merger or consolidation
of the Company with or into another Person, in which the Company is not the surviving entity and in which the stockholders of the Company
immediately prior to such merger or consolidation do not own, directly or indirectly, at least 50% of the voting power of the surviving
entity immediately after such merger or consolidation, (ii) the Company effects any sale, transfer or disposition to another Person of
all or substantially all of its assets in one transaction or a series of related transactions, (iii) pursuant to any tender offer or
exchange offer (whether by the Company or another Person), holders of capital stock tender shares representing more than 50% of the voting
power of the capital stock of the Company and the Company or such other Person, as applicable, accepts such tender for payment, (iv)
the Company consummates a stock purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization,
spin-off or scheme of arrangement) with another Person whereby such other Person acquires more than the 50% of the voting power of the
capital stock of the Company (except for any such transaction in which the stockholders of the Company immediately prior to such transaction
maintain, in substantially the same proportions, the voting power of such Person immediately after the transaction), <I>provided, however</I>,
the foregoing shall not include transactions for which the primary purpose is raising capital, or (v) the Company effects any reclassification
of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged for
other securities, cash or property (other than as a result of a subdivision or combination of shares of Common Stock covered by <U>Section
9(a)</U> above) (in any such case, a &ldquo;<I>Fundamental Transaction</I>&rdquo;), then following such Fundamental Transaction the Holder
shall have the right to receive, upon exercise of this Warrant, the same amount and kind of securities, cash or property as it would
have been entitled to receive upon the occurrence of such Fundamental Transaction if it had been, immediately prior to such Fundamental
Transaction, the holder of the number of Warrant Shares then issuable upon exercise in full of this Warrant without regard to any limitations
on exercise contained herein. In the event the Holder does not exercise this Warrant as contemplated by the foregoing sentence, this
Warrant shall be deemed exercised in full without regard to any limitations on exercise contained herein pursuant to the &ldquo;cashless
exercise&rdquo; provision in Section 10 hereof upon the effective date of the consummation of such Fundamental Transaction.</FONT></P>

<P STYLE="text-indent: 0pt; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="text-indent: 0pt; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
<U>Number of Warrant Shares</U>. Simultaneously with any adjustment to the Exercise Price pursuant to <U>Section 9</U>, the number of
Warrant Shares that may be purchased upon exercise of this Warrant shall be increased or decreased proportionately, so that after such
adjustment the aggregate Exercise Price payable hereunder for the increased or decreased number of Warrant Shares shall be the same as
the aggregate Exercise Price in effect immediately prior to such adjustment.</FONT></P>

<P STYLE="text-indent: 0pt; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0pt; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
<U>Calculations</U>. All calculations under this <U>Section 9</U> shall be made to the nearest one-tenth of one cent or the nearest share,
as applicable.</FONT></P>

<P STYLE="text-indent: 0pt; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0pt; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
<U>Notice of Adjustments</U>. Upon the occurrence of each adjustment pursuant to this <U>Section 9</U>, the Company at its expense will,
at the written request of the Holder, promptly compute such adjustment, in good faith, in accordance with the terms of this Warrant and
prepare a certificate setting forth such adjustment, including a statement of the adjusted Exercise Price and adjusted number or type
of Warrant Shares or other securities issuable upon exercise of this Warrant (as applicable), describing the transactions giving rise
to such adjustments and showing in detail the facts upon which such adjustment is based. Upon written request, the Company will promptly
deliver a copy of each such certificate to the Holder and to the Transfer Agent.</FONT></P>

<P STYLE="text-indent: 0pt; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0pt; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)
<U>Notice of Corporate Events</U>. If, while this Warrant is outstanding, the Company (i) declares a dividend or any other distribution
of cash, securities or other property in respect of its Common Stock, including, without limitation, any granting of rights or warrants
to subscribe for or purchase any capital stock of the Company or any subsidiary, (ii) authorizes or approves, enters into any agreement
contemplating or solicits stockholder approval for any Fundamental Transaction or (iii) authorizes the voluntary dissolution, liquidation
or winding up of the affairs of the Company, then, except if such notice and the contents thereof shall be deemed to constitute material
non-public information, the Company shall deliver to the Holder a notice of such transaction at least ten (10) days prior to the applicable
record or effective date on which a Person would need to hold Common Stock in order to participate in or vote with respect to such transaction;
<I>provided, however</I>, that the failure to deliver such notice or any defect therein shall not affect the validity of the corporate
action required to be described in such notice. In addition, if while this Warrant is outstanding, the Company authorizes or approves,
enters into any agreement contemplating or solicits stockholder approval for any Fundamental Transaction contemplated by <U>Section 9(c)</U>,
other than a Fundamental Transaction under clause (iii) of <U>Section 9(c)</U>, the Company shall deliver to the Holder a notice of such
Fundamental Transaction at least thirty (30) days prior to the date such Fundamental Transaction is consummated. Holder agrees to maintain
any information disclosed pursuant to this <U>Section 9(g)</U> in confidence until such information is publicly available, and shall
comply with applicable law with respect to trading in the Company&rsquo;s securities following receipt any such information.</FONT></P>

<P STYLE="text-indent: 0pt; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0pt; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.
<U>Payment of Exercise Price</U>. Notwithstanding anything contained herein to the contrary, the Holder may, in its sole discretion,
satisfy its obligation to pay the Exercise Price through a &ldquo;cashless exercise&rdquo;, in which event the Company shall issue to
the Holder the number of Warrant Shares in an exchange of securities effected pursuant to Section 3(a)(9) of the Securities Act, as determined
as follows:</FONT></P>

<P STYLE="text-indent: 0pt; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">X
= Y [(A-B)/A]</FONT></P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0pt; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">where:</FONT></P>

<P STYLE="text-indent: 0pt; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0pt; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;X&rdquo;
equals the number of Warrant Shares to be issued to the Holder;</FONT></P>

<P STYLE="text-indent: 0pt; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0pt; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Y&rdquo;
equals the total number of Warrant Shares with respect to which this Warrant is then being exercised;</FONT></P>

<P STYLE="text-indent: 0pt; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0pt; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;A&rdquo;
equals the Closing Sale Price of the shares of Common Stock (as reported by Bloomberg Financial Markets) as of the Trading Day on the
date immediately preceding the Exercise Date; and</FONT></P>

<P STYLE="text-indent: 0pt; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0pt; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;B&rdquo;
equals the Exercise Price then in effect for the applicable Warrant Shares at the time of such exercise.</FONT></P>

<P STYLE="text-indent: 0pt; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0pt; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
purposes of Rule 144 promulgated under the Securities Act, it is intended, understood and acknowledged that the Warrant Shares issued
in a &ldquo;cashless exercise&rdquo; transaction shall be deemed to have been acquired by the Holder, and the holding period for the
Warrant Shares shall be deemed to have commenced, on the Original Issue Date (provided that the Commission continues to take the position
that such treatment is proper at the time of such exercise). In the event that the Registration Statement or another registration statement
registering the issuance of Warrant Shares is, for any reason, not effective at the time of exercise of this Warrant, then the Warrant
may only be exercised through a cashless exercise, as set forth in this <U>Section 10</U>. Except as set forth in <U>Section 5(b)</U>
(Buy-In remedy) and <U>Section 12</U> (payment of cash in lieu of fractional shares), in no event will the exercise of this Warrant be
settled in cash.</FONT></P>

<P STYLE="text-indent: 0pt; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0pt; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.
<U>Limitations on Exercise</U>.</FONT></P>

<P STYLE="text-indent: 0pt; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0pt; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
Notwithstanding anything to the contrary contained herein, the Company shall not effect any exercise of this Warrant, and the Holder
shall not be entitled to exercise this Warrant for a number of Warrant Shares in excess of that number of Warrant Shares which, upon
giving effect or immediately prior to such exercise, would cause (i) the aggregate number of shares of Common Stock beneficially owned
by the Holder, its Affiliates and any Persons who are members of a Section 13(d) group with such Holder or its Affiliates to exceed 4.99%
(the &ldquo;Maximum Percentage&rdquo;) of the total number of issued and outstanding shares of Common Stock of the Company following
such exercise, or (ii) the combined voting power of the securities of the Company beneficially owned by the Holder and its Affiliates
and any other Persons who are members of a Section 13(d) group with such Holder or its Affiliates to exceed the Maximum Percentage of
the combined voting power of all of the securities of the Company then outstanding following such exercise. For purposes of this paragraph,
beneficial ownership and whether a holder is a member of a Section 13(d) group shall be calculated and determined in accordance with
Section 13(d) of the Exchange Act and the rules promulgated thereunder. For purposes of this Warrant, in determining the number of outstanding
shares of Common Stock, the Holder may rely on the number of outstanding shares of Common Stock as reflected in (x) the Company&rsquo;s
most recent Quarterly Report on Form 10-Q or Annual Report on Form 10-K, as the case may be, (y) a more recent public announcement by
the Company or (z) any other written notice by the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding.
Upon the written request of the Holder, the Company shall within five (5) Trading Days confirm in writing or by electronic mail to the
Holder the number of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common Stock shall be
determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder since
the date as of which such number of outstanding shares of Common Stock was reported. By written notice to the Company, the Holder may
from time to time increase or decrease the Maximum Percentage to any other percentage specified not in excess of 19.99% specified in
such notice; provided that any such increase will not be effective until the sixty-first (61st) day after such notice is delivered to
the Company. For purposes of this Section 11(a), the aggregate number of shares of Common Stock or voting securities beneficially owned
by the Holder and its Affiliates and any other Persons who are members of a Section 13(d) group with such Holder or its Affiliates shall
include the shares of Common Stock issuable upon (x) the exercise of this Warrant with respect to which such determination is being made,
but shall exclude the number of shares of Common Stock which would be issuable upon exercise of the remaining unexercised and non-cancelled
portion of this Warrant by the Holder and (y) the exercise or conversion of the unexercised, non-converted or non-cancelled portion of
any other securities of the Company that do not have voting power (including without limitation any securities of the Company which would
entitle the holder thereof to acquire at any time Common Stock, including without limitation any debt, preferred stock, right, option,
warrant or other instrument that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder
thereof to receive, Common Stock), but excluding such shares underlying such instrument which is subject to a limitation on conversion
or exercise analogous to the limitation contained herein.</FONT></P>

<P STYLE="text-indent: 0pt; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0pt; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
This <U>Section 11</U> shall not restrict the number of shares of Common Stock which a Holder may receive or beneficially own in order
to determine the amount of securities or other consideration that such Holder may receive in the event of a Fundamental Transaction as
contemplated in <U>Section 9(c)</U> of this Warrant.</FONT></P>

<P STYLE="text-indent: 0pt; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0pt; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.
<U>No Fractional Shares</U>. No fractional Warrant Shares will be issued in connection with any exercise of this Warrant. In lieu of
any fractional shares that would otherwise be issuable, the number of Warrant Shares to be issued shall be rounded down to the next whole
number and the Company shall pay the Holder in cash the fair market value (based on the Closing Sale Price) for any such fractional shares.</FONT></P>

<P STYLE="text-indent: 0pt; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="text-indent: 0pt; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.
<U>Notices</U>. Any and all notices or other communications or deliveries hereunder (including, without limitation, any Exercise Notice)
shall be in writing and shall be deemed given and effective on the earliest of (i) the date of transmission, if such notice or communication
is delivered via facsimile or e-mail at the facsimile number or e-mail address specified in the books and records of the Transfer Agent
prior to 5:30 P.M., New York City time, on a Trading Day so long as the sender of an e-mail has not received an automated notice of delivery
failure from the proposed recipient&rsquo;s computer server, (ii) the next Trading Day after the date of transmission, if such notice
or communication is delivered via facsimile or e-mail at the facsimile number or e-mail address specified in the books and records of
the Transfer Agent on a day that is not a Trading Day or later than 5:30 P.M., New York City time, on any Trading Day so long as the
sender of an e-mail has not received an automated notice of delivery failure from the proposed recipient&rsquo;s computer server, (iii)
the Trading Day following the date of mailing, if sent by nationally recognized overnight courier service specifying next business day
delivery, or (iv) upon actual receipt by the Person to whom such notice is required to be given, if by hand delivery.</FONT></P>

<P STYLE="text-indent: 0pt; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0pt; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.
<U>Warrant Agent</U>. The Company shall initially serve as warrant agent under this Warrant. Upon thirty (30) days&rsquo; notice to the
Holder, the Company may appoint a new warrant agent. Any corporation into which the Company or any new warrant agent may be merged or
any corporation resulting from any consolidation to which the Company or any new warrant agent shall be a party or any corporation to
which the Company or any new warrant agent transfers substantially all of its corporate trust or shareholders services business shall
be a successor warrant agent under this Warrant without any further act. Any such successor warrant agent shall promptly cause notice
of its succession as warrant agent to be mailed (by first class mail, postage prepaid) to the Holder at the Holder&rsquo;s last address
as shown on the Warrant Register.</FONT></P>

<P STYLE="text-indent: 0pt; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0pt; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.
<U>Miscellaneous</U>.</FONT></P>

<P STYLE="text-indent: 0pt; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0pt; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<U>No Rights as a Stockholder</U>. The Holder, solely in such Person&rsquo;s capacity as a holder of this Warrant, shall not be entitled
to vote or receive dividends or be deemed the holder of share capital of the Company for any purpose, nor shall anything contained in
this Warrant be construed to confer upon the Holder, solely in such Person&rsquo;s capacity as the Holder of this Warrant, any of the
rights of a stockholder of the Company or any right to vote, give or withhold consent to any corporate action (whether any reorganization,
issue of stock, reclassification of stock, consolidation, merger, amalgamation, conveyance or otherwise), receive notice of meetings,
receive dividends or subscription rights, or otherwise, prior to the issuance to the Holder of the Warrant Shares which such Person is
then entitled to receive upon the due exercise of this Warrant. In addition, nothing contained in this Warrant shall be construed as
imposing any liabilities on the Holder to purchase any securities (upon exercise of this Warrant or otherwise) or as a stockholder of
the Company, whether such liabilities are asserted by the Company or by creditors of the Company.</FONT></P>

<P STYLE="text-indent: 0pt; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0pt; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
<U>Authorized Shares</U>. (i) Except and to the extent as waived or consented to by the Holder, the Company shall not by any action,
including, without limitation, amending its certificate or articles of incorporation or through any reorganization, transfer of assets,
consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance
or performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms
and in the taking of all such actions as may be necessary or appropriate to protect the rights of Holder as set forth in this Warrant
against impairment. Without limiting the generality of the foregoing, the Company will (a) not increase the par value of any Warrant
Shares above the amount payable therefor upon such exercise immediately prior to such increase in par value, (b) take all such action
as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and non-assessable Warrant Shares
upon the exercise of this Warrant, and (c) use commercially reasonable efforts to obtain all such authorizations, exemptions or consents
from any public regulatory body having jurisdiction thereof as may be necessary to enable the Company to perform its obligations under
this Warrant.</FONT></P>

<P STYLE="text-indent: 0pt; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0pt; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
Before taking any action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or
in the Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary
from any public regulatory body or bodies having jurisdiction thereof.</FONT></P>

<P STYLE="text-indent: 0pt; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0pt; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
<U>Successors and Assigns</U>. Subject to the restrictions on transfer set forth in this Warrant and compliance with applicable securities
laws, this Warrant may be assigned by the Holder. This Warrant may not be assigned by the Company without the written consent of the
Holder, except to a successor in the event of a Fundamental Transaction. This Warrant shall be binding on and inure to the benefit of
the Company and the Holder and their respective successors and assigns. Subject to the preceding sentence, nothing in this Warrant shall
be construed to give to any Person other than the Company and the Holder any legal or equitable right, remedy or cause of action under
this Warrant. This Warrant may be amended only in writing signed by the Company and the Holder, or their successors and assigns.</FONT></P>

<P STYLE="text-indent: 0pt; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="text-indent: 0pt; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
<U>Amendment and Waiver</U>. Except as otherwise provided herein, the provisions of the Warrants may be amended and the Company may take
any action herein prohibited, or omit to perform any act herein required to be performed by it, only if the Company has obtained the
written consent of the Holder or those registered holders of the Warrants representing no less than a majority of the Warrant Shares
obtainable upon exercise of the Warrants then outstanding.</FONT></P>

<P STYLE="text-indent: 0pt; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0pt; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
<U>Acceptance</U>. Receipt of this Warrant by the Holder shall constitute acceptance of and agreement to all of the terms and conditions
contained herein.</FONT></P>

<P STYLE="text-indent: 0pt; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0pt; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
<U>Governing Law; Jurisdiction</U>. ALL QUESTIONS CONCERNING THE CONSTRUCTION, VALIDITY, ENFORCEMENT AND INTERPRETATION OF THIS WARRANT
SHALL BE GOVERNED BY AND CONSTRUED AND ENFORCED IN ACCORDANCE WITH THE LAWS OF THE STATE OF DELAWARE WITHOUT REGARD TO THE PRINCIPLES
OF CONFLICTS OF LAW THEREOF. EACH OF THE COMPANY AND THE HOLDER HEREBY IRREVOCABLY SUBMITS TO THE EXCLUSIVE JURISDICTION OF THE STATE
AND FEDERAL COURTS SITTING IN THE STATE OF DELAWARE, FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION HEREWITH OR WITH
ANY TRANSACTION CONTEMPLATED HEREBY OR DISCUSSED HEREIN (INCLUDING WITH RESPECT TO THE ENFORCEMENT OF ANY OF THE TRANSACTION DOCUMENTS),
AND HEREBY IRREVOCABLY WAIVES, AND AGREES NOT TO ASSERT IN ANY SUIT, ACTION OR PROCEEDING, ANY CLAIM THAT IT IS NOT PERSONALLY SUBJECT
TO THE JURISDICTION OF ANY SUCH COURT. EACH OF THE COMPANY AND THE HOLDER HEREBY IRREVOCABLY WAIVES PERSONAL SERVICE OF PROCESS AND CONSENTS
TO PROCESS BEING SERVED IN ANY SUCH SUIT, ACTION OR PROCEEDING BY MAILING A COPY THEREOF VIA REGISTERED OR CERTIFIED MAIL OR OVERNIGHT
DELIVERY (WITH EVIDENCE OF DELIVERY) TO SUCH PERSON AT THE ADDRESS IN EFFECT FOR NOTICES TO IT AND AGREES THAT SUCH SERVICE SHALL CONSTITUTE
GOOD AND SUFFICIENT SERVICE OF PROCESS AND NOTICE THEREOF. NOTHING CONTAINED HEREIN SHALL BE DEEMED TO LIMIT IN ANY WAY ANY RIGHT TO
SERVE PROCESS IN ANY MANNER PERMITTED BY LAW. EACH OF THE COMPANY AND THE HOLDER HEREBY WAIVES ALL RIGHTS TO A TRIAL BY JURY.</FONT></P>

<P STYLE="text-indent: 0pt; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0pt; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)
<U>Headings</U>. The headings herein are for convenience only, do not constitute a part of this Warrant and shall not be deemed to limit
or affect any of the provisions hereof.</FONT></P>

<P STYLE="text-indent: 0pt; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0pt; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)
<U>Severability</U>. In case any one or more of the provisions of this Warrant shall be invalid or unenforceable in any respect, the
validity and enforceability of the remaining terms and provisions of this Warrant shall not in any way be affected or impaired thereby,
and the Company and the Holder will attempt in good faith to agree upon a valid and enforceable provision which shall be a commercially
reasonable substitute therefor, and upon so agreeing, shall incorporate such substitute provision in this Warrant.</FONT></P>

<P STYLE="text-indent: 0pt; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[REMAINDER
OF PAGE INTENTIONALLY LEFT BLANK]</FONT></P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>&nbsp;</P>


<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-indent: 0pt; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0pt; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the Company has caused this Warrant to be duly executed by its authorized officer as of the date first indicated above.</FONT></P>

<P STYLE="text-indent: 0pt; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IMMIX BIOPHARMA, INC.</FONT></TD>
    <TD>&nbsp;</TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 45%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD STYLE="width: 50%">&nbsp;</TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    </TR>
  </TABLE>
<P STYLE="text-indent: 0pt; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-indent: 0pt; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>SCHEDULE
1</U></FONT></P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FORM
OF EXERCISE NOTICE</FONT></P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[To
be executed by the Holder to purchase shares Warrant Shares under the Warrant]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; text-align: justify; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ladies
and Gentlemen:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; text-align: justify; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; text-align: justify; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
The undersigned is the Holder of Warrant No. [__] (the &ldquo;<I>Warrant</I>&rdquo;) issued by Immix Biopharma, Inc., a Delaware corporation
(the &ldquo;<I>Company</I>&rdquo;). Capitalized terms used herein and not otherwise defined herein have the respective meanings set forth
in the Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; text-align: justify; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; text-align: justify; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)
The undersigned hereby exercises its right to purchase Warrant Shares pursuant to the Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; text-align: justify; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; text-align: justify; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)
The Holder intends that payment of the Exercise Price shall be made as (check one):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; text-align: justify; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; text-align: justify; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;
Cash Exercise</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; text-align: justify; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; text-align: justify; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;
&ldquo;Cashless Exercise&rdquo; under <U>Section 10</U> of the Warrant</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; text-align: justify; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; text-align: justify; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)
If the Holder has elected a Cash Exercise, the Holder shall pay the sum of $ [__________] in immediately available funds to the Company
in accordance with the terms of the Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; text-align: justify; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; text-align: justify; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)
Pursuant to this Exercise Notice, the Company shall deliver to the Holder Warrant Shares determined in accordance with the terms of the
Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; text-align: justify; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; text-align: justify; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)
By its delivery of this Exercise Notice, the undersigned represents and warrants to the Company that in giving effect to the exercise
evidenced hereby the Holder, its Affiliates and any other Person whose beneficial ownership of Common Stock would be aggregated with
the Holder&rsquo;s for purposes of Section 13(d) of the Exchange Act will not beneficially own in excess of the number of shares of Common
Stock (as determined in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended) permitted to be owned under
<U>Section 11(a)</U> of the Warrant to which this notice relates.</FONT></P>

<P STYLE="text-indent: 0pt; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated: </FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name of Holder: </FONT></TD>
    <TD>&nbsp;</TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;&nbsp;&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:
    </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 45%">&nbsp;&nbsp;</TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:
    </FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:
    </FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="text-indent: 0pt; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; text-align: justify; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Signature
must conform in all respects to name of Holder as specified on the face of the Warrant)</FONT></P>

<P STYLE="text-indent: 0pt; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 10; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; text-align: justify; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>4
<FILENAME>ex5-1.htm
<DESCRIPTION>EX-5.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
5.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><IMG SRC="ex5-1_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
8, 2025</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Immix
Biopharma, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11400
West Olympic Blvd., Suite 200</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Los
Angeles, California 90064</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ladies
and Gentlemen:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have acted as counsel to Immix Biopharma, Inc., a Delaware corporation (the &ldquo;<U>Company</U>&rdquo;), in connection with the preparation
and filing with the Securities and Exchange Commission (the &ldquo;<U>Commission</U>&rdquo;) of a Prospectus Supplement, dated December
8, 2025 (the &ldquo;<U>Prospectus Supplement</U>&rdquo;), to the Base Prospectus (the &ldquo;Base <U>Prospectus,</U>&rdquo; and together
with the Prospectus Supplement, the &ldquo;<U>Prospectus</U>&rdquo;) filed as part of a Registration Statement on Form S-3, Registration
No. 333-269100 (the &ldquo;<U>Registration Statement</U>&rdquo;), initially filed with the Commission on January 3, 2023, that became
effective on January 11, 2023, pursuant to which the Company is offering for sale under the Securities Act of 1933, as amended (the &ldquo;<U>Securities
Act</U>&rdquo;), 19,117,646 shares (the &ldquo;<U>Shares</U>&rdquo;) of common stock, par value $0.0001 per share (the &ldquo;<U>Common
Stock</U>&rdquo;) and pre-funded warrants (the &ldquo;<U>Pre-Funded Warrants</U>&rdquo;) to purchase 490,196 shares of Common Stock at
an exercise price of $0.01 per share (such shares issuable upon exercise of the Pre-Funded Warrants, the &ldquo;<U>Warrant Shares</U>&rdquo;
and together with the Shares and the Pre-Funded Warrants, the &ldquo;<U>Securities</U>&rdquo;) pursuant to an underwriting agreement
dated December 7, 2025 (the &ldquo;<U>Underwriting Agreement</U>&rdquo;) entered into by and between the Company and Morgan Stanley &amp;
Co. LLC, as representative of the several underwriters named therein (the &ldquo;<U>Underwriters</U>&rdquo;). This opinion is being rendered
in connection with the filing of the Prospectus Supplement with the Commission. All capitalized terms used herein and not otherwise defined
shall have the respective meanings given to them in the Registration Statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
opinion is being furnished to you at your request to enable you to fulfill the requirements of Item 601(b)(5) of Regulation S-K promulgated
under the Securities Act, in connection with the Registration Statement, and no opinion is expressed or may be implied herein as to any
matter pertaining to the contents of the Registration Statement, the Prospectus, or Prospectus Supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
reaching the opinions set forth herein, we have examined and are familiar with originals or copies, certified or otherwise identified
to our satisfaction, of such documents and records of the Company and such statutes, regulations and other instruments as we deemed necessary
or advisable for purposes of this opinion, including (i) the Company&rsquo;s Third Amended and Restated Certificate of Incorporation;
(ii) the Company&rsquo;s Amended and Restated Bylaws; (iii) the Registration Statement and the exhibits thereto, and the Prospectus,
(iv) certain resolutions of the Board of Directors and committees thereof of the Company; and (v) such other certificates, instruments,
agreements, and documents as we have considered necessary for purposes of this opinion letter. We have also reviewed such matters of
law as we considered necessary or appropriate as a basis for the opinion expressed below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
rendering this opinion, we have assumed: (i) information contained in documents reviewed by us is true, complete and correct; (ii) the
genuineness and authenticity of all signatures; (iii) the authenticity of all documents submitted to us as originals; (iv) the conformity
to authentic originals of all documents submitted to us as copies; (v) the accuracy, completeness and authenticity of certificates of
public officials; (vi) the obligations of parties other than the Company to the Underwriting Agreement being valid and binding; (vii)
the legal capacity of all natural persons; (viii) that all Securities will be issued and sold in in the manner specified in the Registration
Statement, Prospectus and Prospectus Supplement; and (ix) that at the time of each exercise of the Pre-Funded Warrants, the Company will
have a sufficient number of authorized and unissued shares of the Common Stock available for issuance under the Company&rsquo;s Third
Amended and Restated Certificate of Incorporation to permit full exercise of each of the Pre-Funded Warrants in accordance with their
terms without the breach or violation of any other agreement, commitment or obligation of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
to various questions of fact material to the opinions expressed below, we have, without independent third party verification of their
accuracy, relied in part, and to the extent we deemed reasonably necessary or appropriate, upon the representations and warranties of
the Company and the Underwriters contained in such documents, records, certificates, instruments or representations furnished or made
available to us by the Company or the Underwriters.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
foregoing opinions are limited to the General Corporation Law of the State of Delaware (the &ldquo;<U>DGCL</U>&rdquo;). We express no
opinion herein as to any other laws, statutes, ordinances, rules, or regulations (and in particular, we express no opinion as to any
effect that such other laws, statutes, ordinances, rules, or regulations may have on the opinions expressed herein). No opinion is expressed
herein with respect to the qualification of the Securities under the securities or &lsquo;blue sky&rsquo; laws of any state or any foreign
jurisdiction. This opinion is limited to the matters set forth herein, and no other opinion should be inferred beyond the matters expressly
stated. We have made such examination of the DGCL as we have deemed relevant for purposes of this opinion. We express no opinion as to
any county, municipal, city, town or village ordinance, rule, regulation or administrative decision. We express no opinion as to the
enforceability of the Underwriting Agreement. In rendering the foregoing opinion, we have assumed that the Company will copy with all
applicable notice requirements regarding uncertificated shares provided in the DGCL.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
opinion is based on the laws as in effect on the date hereof, and we disclaim any obligation to advise you of facts, circumstances, events
or developments which hereafter may be brought to our attention and which may alter, affect or modify the opinion expressed herein. We
are not rendering any opinion as to compliance with any federal or state antifraud law, rule or regulation relating to securities, or
to the sale or issuance thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
the basis of the foregoing, and in reliance thereon, we are of the opinion that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            Shares when sold and issued, upon payment therefor, in the manner contemplated by the Prospectus,
                                            will be validly issued, fully paid and nonassessable;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            Pre-Funded Warrants, when sold and issued, upon payment therefor, in the manner contemplated
                                            by the Prospectus, will be valid and binding obligations of the Company, enforceable against
                                            the Company in accordance with their terms: and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            Warrant Shares when issued and delivered by the Company, upon exercise of the Pre-Funded
                                            Warrants, in accordance with the terms thereof, will be validly issued, fully paid and non-assessable.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
hereby consent to the filing of this letter as Exhibit 5.1 to a Current Report on Form 8-K that will be filed by the Company and incorporated
by reference into the Registration Statement and to the reference to our firm in the Prospectus Supplement under the heading &ldquo;<U>Legal
Matters.</U>&rdquo; In giving such consents, we do not hereby admit that we are in the category of persons whose consent is required
under Section 7 of the Securities Act or the rules and regulations of the Commission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 3.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sincerely,</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 3.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 3.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
The Loev Law Firm, PC</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>ex5-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex5-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "# C\# 2(  A$! Q$!_\0
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M..YA>1#AE5P2I]QVH FHHKC/%?C&>PURS\-Z+'%+J]ROFR/+REM%TW,!U)/
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MSM<6PD\LRG'R9/\ =!SD?2J=]I&LG9;Z<XM;7[,JQJDQ AE+99F[L,8 'UH
MZJBN6_LWQ WB<7;W3#3U< 1)+@E53@D=/F8G(]A3(-'\10Z1<3?VFYU.=?\
M5,V8X\R9;:3W"Y4'ITH ZRBN0N=*\2/I[Q6UWY;S78D >4L88@O"YZG+ 9QZ
MFG36/B=K33H89BGV=XGG9I@6F^;+@G^Z!D>] '6T5A2:9>S>)GNVFG6Q2%2D
M:W! >7.3D=A@ ?B:I:';Z[8GS-2BEN)Y9,<3Y2-6))/7H!@#O0!U5%<[XIT_
M4=3C@AL4(*'S YE C+=-LB]67!/3D'%0SZ7JYUNS6$M'I<$*1E(YB,G.6/7/
M& !UZF@#J**YN*QULC46F=C=D2FUE$^(AG(1=@]!C)/?-56TGQ"VF2I'=NEQ
M+Y$*EYLF)%QO<D=6;GIZT ==17,V>G:V(](BN;E\1222WCB;.XX(5!W*\Y_
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M'!P>:9J?C2"R:ZAM]/N[J[@N8;7RD"C=)*-P )/.!R?2@"[_ &?KW_0>B_\
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M>H ;BK&J:P;>]M-+LU$FH7@9T!^['&OWI&]AD #N2!0 S^S]>_Z#T7_@"/\
MXJC^S]>_Z#T7_@"/_BJR=1UW7=,N+UV.ES6-C$TLTGSB10%RH/;<Q[#UJU/X
M@U"WMM$C>"U_M/4-F^U+D8'!D*D_W1Z]: +G]GZ]_P!!Z+_P!'_Q5']GZ]_T
M'HO_  !'_P 52Z-JTE]>:S:RX=M/NO*#H,;E**X'U&['X5GZ+K^IZO?:C!LL
MX6M< V\B2)+&6Y4OG@C&>10!?_L_7O\ H/1?^ (_^*H_L_7O^@]%_P" (_\
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M7R[N:\(DVDO+(NW)./X1P/2L'P_XFO=1M;5+V_('V"35;^904*(S$1QK_=
M)/T]ZF\.:CK.IZEX=M;NZF6:#3VO=0 ; <.=L*N/7&2?I0!K1>"4AT_2;9-3
MN?,TN8RV\I1">000PQAL[CSUS6SJ>GW5]IIM+?4Y[.0XW3QJK.1W'(P*T:*
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M3[31[.RU"[OX$<7-WM\YVD9MVW[O!.!C/:K]% !1110 4444 %%%% !1110
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M%5"JJ[8QD==S'=^%)8P>(;!YHK1',0RRO.F3*4  &,_+OY.?>@#M,+TP/I0
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K **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>immx-20251207.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.3a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 96Mps7xRiXgen8uDanwsWaqMqbP9z5Z8WekhvWBybdn6byguL2fdcyvaXUf20YAL -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:srt-types="http://fasb.org/srt-types/2025" xmlns:IMMX="http://immixbio.com/20251207" elementFormDefault="qualified" targetNamespace="http://immixbio.com/20251207">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://immixbio.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="immx-20251207_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="immx-20251207_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" />
    <import namespace="http://fasb.org/us-gaap/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd" />
    <import namespace="http://fasb.org/us-types/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2024-01-31" schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2025" schemaLocation="https://xbrl.sec.gov/country/2025/country-2025.xsd" />
    <import namespace="http://fasb.org/srt/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd" />
    <import namespace="http://fasb.org/srt-types/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>7
<FILENAME>immx-20251207_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.3a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>8
<FILENAME>immx-20251207_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.3a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="immx-20251207.xsd#Cover" roleURI="http://immixbio.com/role/Cover" />
    <link:presentationLink xlink:type="extended" xlink:role="http://immixbio.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Dec. 07, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec.  07,  2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-41159<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">IMMIX
BIOPHARMA, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001873835<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">45-4869378<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">11400
West Olympic Blvd.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Los
Angeles<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">90064<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(310)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">651-8041<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common
    Stock, par value of $0.0001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">IMMX<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Elected Not To Use the Extended Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>24</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="form8-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immixbio.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="form8-k.htm">form8-k.htm</File>
    <File>immx-20251207.xsd</File>
    <File>immx-20251207_lab.xml</File>
    <File>immx-20251207_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="24">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>16
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "form8-k.htm": {
   "nsprefix": "IMMX",
   "nsuri": "http://immixbio.com/20251207",
   "dts": {
    "inline": {
     "local": [
      "form8-k.htm"
     ]
    },
    "schema": {
     "local": [
      "immx-20251207.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "immx-20251207_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "immx-20251207_pre.xml"
     ]
    }
   },
   "keyStandard": 24,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2025": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 59,
   "unitCount": 3,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 24
   },
   "report": {
    "R1": {
     "role": "http://immixbio.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "AsOf2025-12-07",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form8-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-12-07",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form8-k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://immixbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://immixbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://immixbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://immixbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://immixbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CountryRegion",
     "presentation": [
      "http://immixbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://immixbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://immixbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://immixbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://immixbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://immixbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://immixbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://immixbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://immixbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://immixbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://immixbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://immixbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://immixbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://immixbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://immixbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://immixbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://immixbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://immixbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://immixbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://immixbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://immixbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://immixbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://immixbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://immixbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://immixbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://immixbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://immixbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://immixbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://immixbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://immixbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://immixbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://immixbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://immixbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://immixbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://immixbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://immixbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://immixbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://immixbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://immixbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://immixbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Extension",
     "presentation": [
      "http://immixbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://immixbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://immixbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://immixbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://immixbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://immixbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://immixbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12gTitle",
     "presentation": [
      "http://immixbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://immixbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://immixbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://immixbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://immixbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://immixbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>17
<FILENAME>0001493152-25-026697-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001493152-25-026697-xbrl.zip
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M?%&T421>$QEM)EX TAMF$9DR6'DLV=^#*/M4U/-J2,G?69FGEV!$+=#XL?U
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M%!!!0%0QH?J+E"YT1[2V7:'PJ.W&MS5_8V5$J6.A7"BV$SH8!"ZB<]VAM-C
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M#P.%XTHQ7S'DF!>M7 ;J5R_%VC!4521#'21$@'/W"DJM4U(2')3*C>BH/$3
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MY?OI-@;1#(&] \(H1T-7X 0[!6D3DL?.* &-<_E&H/YF>7OF><%(O-2FUC;
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MM:=#$[AGLSSF]4:6^:FQ-$RPWIO;ZKG# I*O0PTWACMT56@)=R%SK TXA\&
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M!C'0F8CK!N(3P1\E;,-<H8C,8)D*3)_"^V#>%FJ/9$= N\GRR$;^.#&JS[Q
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M:(80?Y@'C,#<L2(@5?:V5#X+M8RSVZES3MDQ89C,)W%&-_RSOLT.6Q-*YDM
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M!<78SHT'3:_4<A7-UNC)Z#=@:EV80JAWH"668;JB8)KEE8Z=5#WHB ]"I-[
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MQ<SA/$US]*$(3.M:%< ;Y96*HD:=%;?1?DW(9Y?>FJ)L-6ZIC7\<4DJL&8^
MB^]S5$^TF7-^THH-I#MB?$^F02A?(,;'ZVR&RDW%221UN(DAQ]](@HF NDY1
MYM=<A0"$Z6N+7$6#HW)R$+HV_>J&W?ETNGSH91K8M5<,?2+1C)"RZ^(SQZ9(
M=*WH@O8E3\CTNP8AK_46M(Q>UQ7,;[.XI9IQ[-6>U5U*Z5DNL"O?F<$+P=NT
MR>\M@Q'NU+8!&/WC%W_'*&^,@A<RZ"\VZ6B2]]-/BRD8+O(Q(C<A"%.>)6'$
M$I;H*Z0(,)5#1DK@G#+-ZL+ZNI7.$\K#A-4P;@_ZRA3I#4KI$9]SI]"/70'
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MFDK7<:$9ITW$#A+50-^7#H.-1:"BK"END+H?=U>[>)6DF&Q+0&X9F'6;Z,P
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MH/;C(UBV1[7[@Z;=;TYQ39[ 9F!7C[)_HA^3%<F#19[CT;F.CM-,99BE)/I
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MXLYU'G1DHQB')-Z9;%\P]< D&40$$^VAD</;-TZAR<UC%=,>W#3V7S!7TVH
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MT=9U41=*LX:.;)V#:;*)V=6^Q> J?GV,<JX"ES[J*JBX2) !^W?]^2R<I=,
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MJOQE&E4C#I]T"8/IE=*VL9'YB,SI"*$90HB?9.9/JBH.IT##>2]3NW2CRE:
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M<MHP$'WO3/]!];MOT)! ()DVF728@383FH3VI2/;,F@B2XXD@^G75_*-BX$
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M):BHQ?;[Y<U-U^*3V*PVB;]6."-BRW\!4$L#!!0    ( ,6+B%LHRDD660<
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M,%UTCGS=V WN_;3%-^Z7>P>KW?(_4$L! A0#%     @ Q8N(6T\=""B^C0
M>JL#  D              ( !     &5X,2TQ+FAT;5!+ 0(4 Q0    ( ,6+
MB%ME5<O<+CH  /-- 0 )              "  >6-  !E>#0M,2YH=&U02P$"
M% ,4    " #%BXA;4+VG:Q,.  !!10  "0              @ $ZR   97@U
M+3$N:'1M4$L! A0#%     @ Q8N(6PWWJNHB&0  @+    L
M ( !=-8  &9O<FTX+6LN:'1M4$L! A0#%     @ Q8N(6PBJDJ H P  X@L
M !$              ( !O^\  &EM;7@M,C R-3$R,#<N>'-D4$L! A0#%
M  @ Q8N(6YAD-N[]"@  ?X8  !4              ( !%O,  &EM;7@M,C R
M-3$R,#=?;&%B+GAM;%!+ 0(4 Q0    ( ,6+B%LHRDD660<  -17   5
M          "  4;^  !I;6UX+3(P,C4Q,C W7W!R92YX;6Q02P4&      <
,!P"C 0  T@4!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>form8-k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="immx-20251207.xsd" xlink:type="simple"/>
    <context id="AsOf2025-12-07">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001873835</identifier>
        </entity>
        <period>
            <startDate>2025-12-07</startDate>
            <endDate>2025-12-07</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:AmendmentFlag contextRef="AsOf2025-12-07" id="Fact000003">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="AsOf2025-12-07" id="Fact000004">0001873835</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="AsOf2025-12-07" id="Fact000009">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="AsOf2025-12-07" id="Fact000010">2025-12-07</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="AsOf2025-12-07" id="Fact000011">IMMIX BIOPHARMA, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="AsOf2025-12-07" id="Fact000012">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="AsOf2025-12-07" id="Fact000013">001-41159</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="AsOf2025-12-07" id="Fact000014">45-4869378</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="AsOf2025-12-07" id="Fact000015">11400 West Olympic Blvd.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="AsOf2025-12-07" id="Fact000016">Suite 200</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="AsOf2025-12-07" id="Fact000017">Los Angeles</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="AsOf2025-12-07" id="Fact000018">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="AsOf2025-12-07" id="Fact000019">90064</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="AsOf2025-12-07" id="Fact000020">(310)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="AsOf2025-12-07" id="Fact000021">651-8041</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="AsOf2025-12-07" id="Fact000022">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="AsOf2025-12-07" id="Fact000023">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="AsOf2025-12-07" id="Fact000024">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="AsOf2025-12-07" id="Fact000025">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="AsOf2025-12-07" id="Fact000026">Common     Stock, par value of $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="AsOf2025-12-07" id="Fact000027">IMMX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="AsOf2025-12-07" id="Fact000028">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="AsOf2025-12-07" id="Fact000029">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="AsOf2025-12-07" id="Fact000030">false</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
